<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">37108392</article-id><article-id pub-id-type="pmc">10139039</article-id><article-id pub-id-type="doi">10.3390/ijms24087228</article-id><article-id pub-id-type="publisher-id">ijms-24-07228</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Aluminium in the Human Brain: Routes of Penetration, Toxicity, and Resulting Complications</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4604-6330</contrib-id><name><surname>Bryli&#x00144;ski</surname><given-names>&#x00141;ukasz</given-names></name><xref rid="af1-ijms-24-07228" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5140-0990</contrib-id><name><surname>Kostelecka</surname><given-names>Katarzyna</given-names></name><xref rid="af1-ijms-24-07228" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6444-5645</contrib-id><name><surname>Woli&#x00144;ski</surname><given-names>Filip</given-names></name><xref rid="af2-ijms-24-07228" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0867-6315</contrib-id><name><surname>Duda</surname><given-names>Piotr</given-names></name><xref rid="af1-ijms-24-07228" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2770-5524</contrib-id><name><surname>G&#x000f3;ra</surname><given-names>Joanna</given-names></name><xref rid="af1-ijms-24-07228" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5692-9770</contrib-id><name><surname>Granat</surname><given-names>Micha&#x00142;</given-names></name><xref rid="af1-ijms-24-07228" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6881-3161</contrib-id><name><surname>Flieger</surname><given-names>Jolanta</given-names></name><xref rid="af3-ijms-24-07228" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4184-9305</contrib-id><name><surname>Teresi&#x00144;ski</surname><given-names>Grzegorz</given-names></name><xref rid="af4-ijms-24-07228" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7637-6387</contrib-id><name><surname>Buszewicz</surname><given-names>Grzegorz</given-names></name><xref rid="af4-ijms-24-07228" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Sitarz</surname><given-names>Ryszard</given-names></name><xref rid="af5-ijms-24-07228" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1372-8987</contrib-id><name><surname>Baj</surname><given-names>Jacek</given-names></name><xref rid="af6-ijms-24-07228" ref-type="aff">6</xref><xref rid="c1-ijms-24-07228" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Scudiero</surname><given-names>Rosaria</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-07228"><label>1</label>Student Scientific Group, Department of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland</aff><aff id="af2-ijms-24-07228"><label>2</label>Student Scientific Group, Department of Anatomy, Medical University of Lublin, ul. Jaczewskiego 4, 20-090 Lublin, Poland</aff><aff id="af3-ijms-24-07228"><label>3</label>Department of Analytical Chemistry, Medical University of Lublin, Chod&#x0017a;ki 4A, 20-093 Lublin, Poland</aff><aff id="af4-ijms-24-07228"><label>4</label>Department of Forensic Medicine, Medical University of Lublin, Jaczewskiego 8b, 20-090, Lublin, Poland</aff><aff id="af5-ijms-24-07228"><label>5</label>I Department of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, 20-059 Lublin, Poland</aff><aff id="af6-ijms-24-07228"><label>6</label>Department of Anatomy, Medical University of Lublin, ul. Jaczewskiego 4, 20-090 Lublin, Poland</aff><author-notes><corresp id="c1-ijms-24-07228"><label>*</label>Correspondence: <email>jacek.baj@umlub.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2023</year></pub-date><volume>24</volume><issue>8</issue><elocation-id>7228</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2023</year></date><date date-type="rev-recd"><day>31</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>4</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Aluminium (Al) is the most ubiquitous metal in the Earth&#x02019;s crust. Even though its toxicity is well-documented, the role of Al in the pathogenesis of several neurological diseases remains debatable. To establish the basic framework for future studies, we review literature reports on Al toxicokinetics and its role in Alzheimer&#x02019;s disease (AD), autism spectrum disorder (ASD), alcohol use disorder (AUD), multiple sclerosis (MS), Parkinson&#x02019;s disease (PD), and dialysis encephalopathy (DE) from 1976 to 2022. Despite poor absorption via mucosa, the biggest amount of Al comes with food, drinking water, and inhalation. Vaccines introduce negligible amounts of Al, while the data on skin absorption (which might be linked with carcinogenesis) is limited and requires further investigation. In the above-mentioned diseases, the literature shows excessive Al accumulation in the central nervous system (AD, AUD, MS, PD, DE) and epidemiological links between greater Al exposition and their increased prevalence (AD, PD, DE). Moreover, the literature suggests that Al has the potential as a marker of disease (AD, PD) and beneficial results of Al chelator use (such as cognitive improvement in AD, AUD, MS, and DE cases).</p></abstract><kwd-group><kwd>aluminium</kwd><kwd>human brain</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>autism spectrum disorder</kwd><kwd>alcohol use disorder</kwd><kwd>multiple sclerosis</kwd><kwd>Parkinson&#x02019;s disease</kwd><kwd>dialysis encephalopathy</kwd></kwd-group><funding-group><award-group><funding-source>Medical University of Lublin</funding-source><award-id>DS 466</award-id></award-group><funding-statement>This research was funded by the Medical University of Lublin, grant number DS 466.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-07228"><title>1. Introduction</title><p>Aluminium is the third most common element and the most ubiquitous metal of the Earth&#x02019;s crust, constituting over 8% of its mass [<xref rid="B1-ijms-24-07228" ref-type="bibr">1</xref>]. However, it is not essential for human metabolism [<xref rid="B2-ijms-24-07228" ref-type="bibr">2</xref>,<xref rid="B3-ijms-24-07228" ref-type="bibr">3</xref>], and adversely it can be toxic for the human organism, including the brain [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B5-ijms-24-07228" ref-type="bibr">5</xref>]. This fact is worrying, considering that we live in the &#x02018;Aluminium age&#x02019;, where exposure to this extensively used metal is inevitable and burgeoning [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>]. Absorbed via various routes, Al can display toxic properties, some of which can be associated with the pathogenesis of Parkinson&#x02019;s disease (PD), Alzheimer&#x02019;s disease (AD), autism spectrum disorder (ASD), alcohol use disorder (AUD), multiple sclerosis (MS), and dialysis encephalopathy (DE). Therefore, according to the literature sources, Al concentration could be used as a marker of certain diseases (AD, PD), and possible benefits from the use of Al chelators (AD, AUD, MS, DE) are possible.</p><p>In this review, we aimed to collect data regarding the sources of exposure to Al, routes of its absorption into the body, and the molecular mechanism of its toxic effects in the pathogenesis of several neurological diseases. We performed the literature review using PubMed and UpToDate based on international papers in the English language. Articles published between 1976 and 2022 were considered. We used the following phrases: Aluminium, Aluminium exposure, Aluminium environment, Aluminium in brain, Aluminium gastrointestinal absorption, Aluminium lung absorption, Aluminium intake, Aluminium skin absorption, Aluminium antacids, Aluminium vaccines, Aluminium drugs, Aluminium excretion, Aluminium drinking water, Occupational exposure to Al, Aluminium toxicity, Parkinson&#x02019;s disease, Alzheimer&#x02019;s disease, autism spectrum disorder, alcohol use disorder, multiple sclerosis, and dialysis encephalopathy. The main focus was on the articles from international scientific journals available through Pubmed, UpToDate, and Google Scholar. Guidelines from the World Health Organization (WHO), Agency for Toxic Substances and Disease Registry (ATSDR), EFSA, and SCCS were used. Finally, the results of 125 articles, which described Al sources and ways of elimination, toxic mechanisms, and the role of Al in the pathogenesis of several diseases: AD, ASD, AUD, MS, PD, and DE, were collected. Thus, the current knowledge related to clinical trials, systematic reviews, meta-analyses, and case reports was taken into account.</p><sec id="sec1dot1-ijms-24-07228"><title>1.1. Al Sources and Elimination</title><p>The primary natural sources of Al are rocks (such as bauxite, silicates, and cryolite) and, to a lesser extent, surface, and subsurface waters and soils, to which Al migrates as a consequence of natural weathering processes and volcanic activity [<xref rid="B7-ijms-24-07228" ref-type="bibr">7</xref>,<xref rid="B8-ijms-24-07228" ref-type="bibr">8</xref>,<xref rid="B9-ijms-24-07228" ref-type="bibr">9</xref>]. These phenomena belonging to the &#x02018;geochemical cycle&#x02019; were never a source of a biologically reactive Al &#x02018;throughout biochemical evolution&#x02019;, which justifies its non-essentiality for living organisms [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>]. The lithosphere-to-biosphere transfer, which depends on the incorporation of Al into the &#x02018;biogeochemical cycle&#x02019;, is predominantly the effect of either indirect or direct human activity [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>,<xref rid="B10-ijms-24-07228" ref-type="bibr">10</xref>]. The first involves the influence of acid rains releasing Al ions into the environment, and the other consists of Al extraction from biologically inert ores for industrial purposes [<xref rid="B10-ijms-24-07228" ref-type="bibr">10</xref>]. Among the latter, we might distinguish materials used for vehicle and airplane production, construction and building materials, packaging, electrical devices, foods, drinking water, cosmetics, personal care products, medicaments, and a variety of utensils [<xref rid="B7-ijms-24-07228" ref-type="bibr">7</xref>].</p><p>Nevertheless, the above-mentioned sources vary significantly in terms of Al content and route and degree of absorption of this element. Moreover, each individual is differently exposed to these sources, which translates into the distinct burden of biologically reactive Al that could impact human health. The main penetration routes for Al into the human organism are oral intake (either from foods or beverages) and inhalation. Furthermore, the digestive tract is the leading Al absorption site for the general population [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B11-ijms-24-07228" ref-type="bibr">11</xref>]. It is worth mentioning that aspired Al, which is available mostly for occupationally exposed populations, for instance, during mining and processing of Al ores, welding, cutting, etc. [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>], could be absorbed into the bloodstream either directly through the lung tissue [<xref rid="B11-ijms-24-07228" ref-type="bibr">11</xref>] and respiratory epithelium of the nasal cavity or enter the gastrointestinal tract via mucociliary clearance and swallowing. The nasal cavity also contains the olfactory epithelium, which makes up the direct pathway for Al into the brain [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>]. <xref rid="ijms-24-07228-f001" ref-type="fig">Figure 1</xref> shows the main routes for Al into the brain.</p><p>Considering food ingestion, it constitutes a source of about 50% of Al&#x02019;s Tolerable Weekly Intake (TWI) settled by the European Food Safety Authority (EFSA) [<xref rid="B12-ijms-24-07228" ref-type="bibr">12</xref>]. Among food sources, vegetables contribute to the most Al exposure [<xref rid="B13-ijms-24-07228" ref-type="bibr">13</xref>] (see <xref rid="ijms-24-07228-t001" ref-type="table">Table 1</xref> and <xref rid="ijms-24-07228-t002" ref-type="table">Table 2</xref>).</p><p>It should be kept in mind that the presence of Al in foods is a result of both original content (from environmental sources and food additives) and the following interaction with Al-containing materials used for food packaging and cooking [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B10-ijms-24-07228" ref-type="bibr">10</xref>]. Drinking water contributes to the total oral exposure to Al, usually less than 5% [<xref rid="B25-ijms-24-07228" ref-type="bibr">25</xref>]. Al content in drinking water is a sum of Al present in all natural waters and the one coming from Al salts used for water treatment processes [<xref rid="B9-ijms-24-07228" ref-type="bibr">9</xref>]. The usually achievable Al concentrations in drinking water (0.1&#x02013;0.2 mgAl/L) are close to the acceptable levels (0.05&#x02013;0.2 mgAl/L) settled independently by many countries [<xref rid="B9-ijms-24-07228" ref-type="bibr">9</xref>,<xref rid="B25-ijms-24-07228" ref-type="bibr">25</xref>]. It is worth noting that Al is absorbed in merely about 0.1% and 0.3% of food and drinking water, respectively [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>]. The Al uptake itself depends on several factors listed in <xref rid="ijms-24-07228-t003" ref-type="table">Table 3</xref>.</p><p>As a consequence of using widespread over-the-counter antacids, Al ingestion might exceed that in food and beverages by over 100-fold [<xref rid="B26-ijms-24-07228" ref-type="bibr">26</xref>], although the absorption is usually in the range of 0.01&#x02013;1%. It was estimated that orange juice could increase Al absorption from antacid drugs by 8-fold and that citric acid increases the intake by up to 50-fold [<xref rid="B27-ijms-24-07228" ref-type="bibr">27</xref>].</p><p>To a lesser degree, Al might enter the system through other routes. Al exists in thousands of formulations of cosmetics and personal care products, such as antiperspirants, lipsticks, liquid makeup foundations, toothpaste, etc. There are very few studies concerning Al absorption through the skin [<xref rid="B28-ijms-24-07228" ref-type="bibr">28</xref>]; however, the Scientific Committee on Consumer Safety (SCCS) recommended safe limits for sprayable and non-sprayable Al-containing cosmetic products [<xref rid="B29-ijms-24-07228" ref-type="bibr">29</xref>]. Among pharmaceuticals, apart from previously mentioned antacids, Al is also functioning as a vaccine adjuvant. However, it should be taken into account that the vaccination itself is a rather sporadic event and that the Al content in a single vaccine dose is limited to 1.25 mg. It was stated that the risk of Al toxicity for the most vulnerable group, which is infants, and therefore for the general population, is minimal compared to the benefits related to the vaccination itself [<xref rid="B30-ijms-24-07228" ref-type="bibr">30</xref>] and that there are no indications related to neurotoxicity for the elimination of Al from the vaccines [<xref rid="B31-ijms-24-07228" ref-type="bibr">31</xref>]. In addition, formerly, patients with chronic kidney disease formed a substantial group exposed to Al due to contamination of dialysis water with Al compounds and ingestion of Al-containing phosphate binders. Currently, it is no more a common issue in many countries due to the removal of Al from the water used for dialysis and new phosphate binders free from Al [<xref rid="B32-ijms-24-07228" ref-type="bibr">32</xref>].</p><p>Al is excreted from the body through numerous routes, depending on whether it has been absorbed into the bloodstream or where it had been deposited in the organism. The absorbed fraction is eliminated (as the Al ion) in 95% with urine. Unabsorbed Al located in the gastrointestinal tract, either ingested or coming from the aforesaid mucociliary clearance, is excreted via the feces [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>,<xref rid="B12-ijms-24-07228" ref-type="bibr">12</xref>]. Other possible routes of Al elimination comprise the skin, hair, sebum, nails, sweat, semen, milk, and bile [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>].</p></sec><sec id="sec1dot2-ijms-24-07228"><title>1.2. Mechanisms of Aluminium Toxic Effects</title><p>Although we know for sure that Al accumulates in the brain [<xref rid="B33-ijms-24-07228" ref-type="bibr">33</xref>,<xref rid="B34-ijms-24-07228" ref-type="bibr">34</xref>], it is not fully understood how it reaches it. Possibly, similar to other nonessential metals, it hijacks physiological transportation and absorption mechanisms [<xref rid="B35-ijms-24-07228" ref-type="bibr">35</xref>]. The major fraction of Al (about 90%) after absorption is bounded by serum transferrin (Tf), which is also responsible for the transportation of iron (Fe) cations. This protein can intercede in the transportation of Al through the blood&#x02013;brain barrier (BBB) by means of transferrin receptor (TfR)-mediated endocytosis. Most of the remaining 10% circulates as Al citrate, which is much more prominent in cerebrospinal fluid (CSF). This suggests the existence of yet another transportation mechanism independent of Tf [<xref rid="B36-ijms-24-07228" ref-type="bibr">36</xref>]. In addition, Al is capable of selectively increasing the rate of diffusion across BBB [<xref rid="B37-ijms-24-07228" ref-type="bibr">37</xref>]. It was demonstrated that some blood vessels display a greater affinity for Al accumulation than others. Those include brain arteries lined with human brain microvessel endothelial cells, especially the posterior cerebral artery that supplies the hippocampus. Besides the hippocampal area, Al is mostly deposited in the cerebellum and cortex [<xref rid="B36-ijms-24-07228" ref-type="bibr">36</xref>,<xref rid="B38-ijms-24-07228" ref-type="bibr">38</xref>]. Additionally, Al can probably reach the brain directly through the continuity of the olfactory epithelium, the olfactory nerve, and the olfactory bulb [<xref rid="B6-ijms-24-07228" ref-type="bibr">6</xref>].</p><p>Considering the aforementioned toxicity, Al cations and their compounds can disrupt crucial cell functions and processes. Thus, the effects of exposure to Al are visible on a molecular and systemic level. The neurotoxic features of chronic Al toxicity are well-documented [<xref rid="B39-ijms-24-07228" ref-type="bibr">39</xref>]. In the mammalian brain, intracisternal [<xref rid="B40-ijms-24-07228" ref-type="bibr">40</xref>] and oral [<xref rid="B41-ijms-24-07228" ref-type="bibr">41</xref>] Al supply results in a neurofibrillary degeneration pattern that could resemble the neurofibrillary tangles (NFTs) present in Alzheimer&#x02019;s disease (AD) patients [<xref rid="B42-ijms-24-07228" ref-type="bibr">42</xref>]. However, Oshima et al. [<xref rid="B43-ijms-24-07228" ref-type="bibr">43</xref>] proved that after chronic oral Al ingestion, promoted tau aggregation, apoptosis, and neurological dysfunctions were only observed in transgenic mice already having tau aggregation, contrary to wild-type mice.</p><p>When confronted with Al cations, protein polypeptides can either denature or undergo conformational or structural alternation, as in &#x003b2;-amyloid plaques. Moreover, Al blocks the proteolytic degradation of amyloid, enhancing its deposition and aggregation [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B28-ijms-24-07228" ref-type="bibr">28</xref>,<xref rid="B44-ijms-24-07228" ref-type="bibr">44</xref>,<xref rid="B45-ijms-24-07228" ref-type="bibr">45</xref>,<xref rid="B46-ijms-24-07228" ref-type="bibr">46</xref>] and increasing its permeability in the striatum and thalamus [<xref rid="B47-ijms-24-07228" ref-type="bibr">47</xref>]. Furthermore, it was demonstrated that Al promotes phosphorylation and aggregation of phosphorylated proteins such as Tau protein. Additionally, according to some studies, it increases the expression of the precursor amyloid protein (APP), &#x003b2;-40, and &#x003b2;-42 fragments and prolongs A&#x003b2;-42 half-life in blood [<xref rid="B47-ijms-24-07228" ref-type="bibr">47</xref>,<xref rid="B48-ijms-24-07228" ref-type="bibr">48</xref>,<xref rid="B49-ijms-24-07228" ref-type="bibr">49</xref>], though results have not always been consistent [<xref rid="B28-ijms-24-07228" ref-type="bibr">28</xref>,<xref rid="B36-ijms-24-07228" ref-type="bibr">36</xref>]. Al can influence the activity of important neuronal enzymes such as Alkaline Phosphatase and Acetylocholinesterase as well as decrease neurotransmission. Moreover, it increases the expression of Cyclin D and Cathepsin D, which are essential cell cycle proteins [<xref rid="B34-ijms-24-07228" ref-type="bibr">34</xref>,<xref rid="B36-ijms-24-07228" ref-type="bibr">36</xref>]. Several Al compounds exerted neuronal and glial apoptosis in hippocampal cell cultures [<xref rid="B50-ijms-24-07228" ref-type="bibr">50</xref>]. On the contrary, in other studies involving mice, excessive oral Al supply did not increase either A&#x003b2; or tau protein accumulation [<xref rid="B51-ijms-24-07228" ref-type="bibr">51</xref>] or altered spatial learning and memory with no effect on neurogenesis [<xref rid="B52-ijms-24-07228" ref-type="bibr">52</xref>]. Noticeably, Al-maltolate-treated aged rabbits are suggested as the best animal models for Al-induced AD [<xref rid="B53-ijms-24-07228" ref-type="bibr">53</xref>]. </p><p>Al interferes with the energy metabolism of hepatocytes by impeding ATP production, inhibiting glycolysis and the Krebs cycle, and promoting protein and lipid oxidation. Additionally, it damages metal processing causing Fe overload, which boosts oxidative stress and, as a result, causes DNA damage and cell death [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B36-ijms-24-07228" ref-type="bibr">36</xref>]. Moreover, Al causes apoptosis of lymphocytes (immunosuppression) and erythrocytes. It can affect bone mineralization and formation by increasing osteoclast activity, decreasing osteoblast function (via interacting with the Wnt/&#x003b2;-catenin signaling pathway, bone morphogenic protein 2 (BMP-2) signaling pathway, and transforming growth factor-beta 1 (TGF-&#x003b2;1) expression), and inhibiting vitamin D biological properties (for example by blocking stimulation of synthesis of osteocalcin in osteoblasts). It is worth mentioning that the aforesaid BMP-2 and TGF-&#x003b2;1 pathways are essential for proper cartilage formation. Some studies linked exposure to Al with hypertension, ischemic strokes, and endocrine disruptions (Al affects the secretion of parathormone, testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, norepinephrine, cortisol, thyroid hormones, and insulin). Furthermore, Al concentration in the cell nucleus negatively impacts proliferation and differentiation, and thus it is considered genotoxic. This may be connected with the metastatic process of breast cancer (activating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14)). Lastly, Al is considered a proinflammatory and proapoptotic agent, up-regulating various cytokines such as Interleukin-1&#x003b2; and tumor necrosis factor &#x003b1; (TNF&#x003b1;) in numerous tissues [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B28-ijms-24-07228" ref-type="bibr">28</xref>,<xref rid="B54-ijms-24-07228" ref-type="bibr">54</xref>,<xref rid="B55-ijms-24-07228" ref-type="bibr">55</xref>,<xref rid="B56-ijms-24-07228" ref-type="bibr">56</xref>,<xref rid="B57-ijms-24-07228" ref-type="bibr">57</xref>]. </p><p>Among the systemic effects of Al, one may mention the following:<list list-type="bullet"><list-item><p>Pulmonary lesions&#x02014;Al has been connected with disorders such as granulomatosis and fibrosis of the lungs, pneumonia, pulmonary edema, and pulmonary alveolar proteinosis. Possibly it is also connected with asthma;</p></list-item><list-item><p>Cardiovascular effects&#x02014;in the case of Al phosphide intoxication, myocarditis, hypokinesia, left ventricular thrombosis, and stroke were reported. Among pregnant women, greater Al hair concentration correlated with a higher incidence of congenital heart defects in their offspring;</p></list-item><list-item><p>Hematologic effects&#x02014;include depressed erythropoiesis and subsequent anemia;</p></list-item><list-item><p>Musculoskeletal effects&#x02014;exposure to Al can cause macrophagic myofasciitis associated with arthromyalgia and chronic fatigue syndrome. Osteoporosis, rickets, exostosis, osteodystrophy, and osteitis fibrosa are also triggered by this metal;</p></list-item><list-item><p>Neurological effects&#x02014;higher Al hair concentrations were connected with dialysis encephalopathy (DE), Parkinson&#x02019;s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and autism spectrum disorder (ASD) [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>,<xref rid="B56-ijms-24-07228" ref-type="bibr">56</xref>,<xref rid="B58-ijms-24-07228" ref-type="bibr">58</xref>,<xref rid="B59-ijms-24-07228" ref-type="bibr">59</xref>].</p></list-item></list></p></sec></sec><sec id="sec2-ijms-24-07228"><title>2. Alzheimer&#x02019;s Disease</title><p>AD is the most common cause of dementia, contributing to 60&#x02013;70% of its cases [<xref rid="B60-ijms-24-07228" ref-type="bibr">60</xref>]. Between 2011 and 2050, the number of AD patients is predicted to rise threefold, with an estimated over 100 million patients by 2050 [<xref rid="B61-ijms-24-07228" ref-type="bibr">61</xref>]. Regarding anatomopathological analyses, Al was shown to appear in the core of senile plaques within the hippocampus and temporal lobes in AD patients [<xref rid="B62-ijms-24-07228" ref-type="bibr">62</xref>]. Compared with non-demented patients, Al concentration in brain samples of AD sufferers was reported higher in the hippocampus [<xref rid="B63-ijms-24-07228" ref-type="bibr">63</xref>] and temporal gyri [<xref rid="B64-ijms-24-07228" ref-type="bibr">64</xref>], as compared with non-AD patients (<xref rid="ijms-24-07228-t004" ref-type="table">Table 4</xref>). However, Akatsu et al. [<xref rid="B65-ijms-24-07228" ref-type="bibr">65</xref>] found no statistically significant differences between AD patients and non-demented patients in the hippocampus and amygdala. Virk et al. [<xref rid="B66-ijms-24-07228" ref-type="bibr">66</xref>], in a 2015 meta-analysis, compared the levels of Al in the brain, serum, and CSF of AD and non-AD individuals. AD patients had higher Al levels in all of the analyzed tissues, and those authors suggested that plasma Al levels could be an early marker of AD development [<xref rid="B66-ijms-24-07228" ref-type="bibr">66</xref>]. </p><p>However, despite many reports on AD-promoting action and being the most widely studied environmental agent in the pathogenesis of AD [<xref rid="B66-ijms-24-07228" ref-type="bibr">66</xref>], the link between Al and AD remains a source of intense scientific debate [<xref rid="B39-ijms-24-07228" ref-type="bibr">39</xref>,<xref rid="B67-ijms-24-07228" ref-type="bibr">67</xref>,<xref rid="B68-ijms-24-07228" ref-type="bibr">68</xref>]. The majority of epidemiological studies suggest a link between AD and chronic exposure to Al [<xref rid="B39-ijms-24-07228" ref-type="bibr">39</xref>], specifying drinking water and occupational exposure to Al as the two most common sources of chronic exposure to Al [<xref rid="B68-ijms-24-07228" ref-type="bibr">68</xref>]. </p><p>In 2016, Wang et al. [<xref rid="B68-ijms-24-07228" ref-type="bibr">68</xref>] published a meta-analysis including 10567 participants from eight epidemiological studies published up to June 2015. The chronic exposure to Al via drinking water or the subject&#x02019;s occupation was associated with an increased risk of AD development, with OR of 1.95 (95% CI, 1.47&#x02013;2.59) and 1.25 (95% CI, 0.80&#x02013;1.94), respectively [<xref rid="B68-ijms-24-07228" ref-type="bibr">68</xref>]. However, a 2015 meta-analysis found no link between AD and occupational exposure to Al among 1056 participants [<xref rid="B69-ijms-24-07228" ref-type="bibr">69</xref>]. In two large prospective studies, Rodeau et al. [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>,<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>] investigated the links between Al and silica exposure on the development of dementia and AD among 3777 subjects aged at least 65 years (PAQUID cohort). The second study comprised additional 400 subjects from the ALMA+ cohort, but no data regarding AD were provided in this group. In the first study, evaluation was made among 2698 patients after a mean follow-up of 5.9 years [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>], while, in the second study, 1677 subjects were analyzed after a mean of 11.3 years [<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>]. In the first study, the authors found an epidemiological link between high water Al concentration (at least 0.1 mg/L) and higher AD prevalence with an RR of 2.20 (95% CI, 1.24&#x02013;3.84) [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>]. Similarly, in the second study, the authors found an epidemiological link between high daily water Al consumption (at least 0.1 mg/day) and higher AD prevalence (RR of 3.35 with 95%CI of 1.49&#x02013;7.52) [<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>]. </p><p>Al hypothesis in AD development is linked with the therapeutic use of Al chelators. The first widely used Al chelator was deferoxamine (DFO), and despite reported clinical usefulness in AD, its adverse effects and administration via long-lasting injection limited its usability [<xref rid="B72-ijms-24-07228" ref-type="bibr">72</xref>]. However, the recent literature review by Agrawal et al. [<xref rid="B73-ijms-24-07228" ref-type="bibr">73</xref>] on intranasal AD drugs pointed clearly to intranasal DFO as a potential candidate for AD treatment. Other metal chelators that were evaluated in AD treatment are silicon (Si) compounds, which are natural antagonists of Al [<xref rid="B74-ijms-24-07228" ref-type="bibr">74</xref>]. The first study that showed reduced Al burden in AD after Si-rich mineral water drinking was published in 2006 by Exley et al. [<xref rid="B75-ijms-24-07228" ref-type="bibr">75</xref>]. Among subsequent studies, Davenward et al. [<xref rid="B74-ijms-24-07228" ref-type="bibr">74</xref>] tested the impact of 12-week Si-rich mineral water drinking treatment on Al-body-burden among 15 AD and 14 non-AD participants. Such therapy reduced the body Al burden in both groups and improved cognitive outcomes in three of the AD sufferers [<xref rid="B74-ijms-24-07228" ref-type="bibr">74</xref>]. Results of two above-mentioned epidemiological studies by Rondeau et al. [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>,<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>] showed that high water silica concentration (at least 11.25 mg/L) [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>], or 10 mg/day increase in water silica [<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>] were associated with lower AD prevalence with RR of 0.69 (95%CI, 0.52&#x02013;0.94) [<xref rid="B70-ijms-24-07228" ref-type="bibr">70</xref>] and 0.88 (95% CI, 0.79&#x02013;0.99) [<xref rid="B71-ijms-24-07228" ref-type="bibr">71</xref>], respectively. AD was also suggested to be linked with Al-containing antacid drugs. However, in a meta-analysis comprising seven case-control and two cohort studies, regular Al-containing antacids use was not associated with AD [<xref rid="B67-ijms-24-07228" ref-type="bibr">67</xref>].</p><table-wrap position="anchor" id="ijms-24-07228-t004"><object-id pub-id-type="pii">ijms-24-07228-t004_Table 4</object-id><label>Table 4</label><caption><p>The concentration of aluminium in the tissues of patients with particular neurological diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Tissue</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Level/Concentration in Tissue of the Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Level/Concentration in Tissue of Control Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Additional Information</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hippocampus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000357 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00009 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with AD and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B63-ijms-24-07228" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">the temporal lobe of the brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0019&#x02013;0.0168 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00016&#x02013;0.0018 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with AD and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B64-ijms-24-07228" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">occipital lobe; <break/>frontal lobe; <break/>temporal lobe; <break/>parietal lobe;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00382 mg/g;<break/>0.00230 &#x003bc;g/g;<break/>0.00279 mg/g;<break/>0.00382 mg/g;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B76-ijms-24-07228" ref-type="bibr">76</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ASD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">the temporal lobe of the brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0009&#x02013;0.0016 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00016&#x02013;0.0018 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The authors found no association between ASD and Al concentration in temporal gyri.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B64-ijms-24-07228" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">total brain content; <break/>thalamus; <break/>inferior longitudinal fasciculus; <break/>insula; <break/>superior longitudinal fasciculus;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00159 mg/g;<break/>0.00405 mg/g;<break/>0.00348 mg/g;<break/>0.00241 mg/g;<break/>0.00108 mg/g;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All control samples displayed Al content below detection limits.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In this research, authors also showed that&#x000a0;the Al levels in the liver displayed no significant difference between AUD and control subjects.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B77-ijms-24-07228" ref-type="bibr">77</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0012 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0006 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with MS and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B78-ijms-24-07228" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">scalp hair samples</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00376 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00449 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with MS and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B79-ijms-24-07228" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">urine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.51 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the level of Al between patients with MS and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B80-ijms-24-07228" ref-type="bibr">80</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">brain </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00159 mg/g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0044 mg/g;<break/>0.0027 mg/g;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean brain concentrations of Al were 0,00159 mg/g, 0,0044 mg/g, and 0,0027 mg/g among patients dying from dialysis encephalopathy, among the dialyzed control group, and among uraemic patients who were not dialyzed, respectively.<break/>The differences in the concentration of Al between patients with DE and the control groups were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B81-ijms-24-07228" ref-type="bibr">81</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">muscle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.8 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.2 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with DE and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B82-ijms-24-07228" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
trabecular-bone
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.5 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The differences in the concentration of Al between patients with DE and the control group were statistically significant.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B82-ijms-24-07228" ref-type="bibr">82</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
brain grey-matter
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 ppm<break/>6.5 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2 ppm</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean brain concentrations of Al were 25 ppm, 6.5 ppm, and 2.2 ppm among uremic patients on dialysis who died of a neurologic syndrome of unknown cause, among uremic patients on dialysis who died of other causes, and among control subjects, respectively.<break/>Mean brain concentrations of Al were significantly higher in both uraemic groups as compared to controls. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B82-ijms-24-07228" ref-type="bibr">82</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ASD&#x02014;Autism spectrum disorder; AUD&#x02014;Alcohol use disorder; DE&#x02014;Dialisys encephalopathy; MS&#x02014;Multiple sclerosis.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3-ijms-24-07228"><title>3. Autism Spectrum Disorder</title><p>ASD is a neurodevelopmental disorder associated mainly with persistent deficits in social communication and repetitive, inflexible patterns of behavior. Depending on geographical region and diagnostic criteria, its prevalence in Asia, Europe, and the USA ranges from 0.2% to 2.5%. Worryingly, a significant increase in diagnosed ASD has been seen since the late 1990s [<xref rid="B83-ijms-24-07228" ref-type="bibr">83</xref>], with a more than 20-fold increase between the 1970 and 2005 birth years in USA population [<xref rid="B84-ijms-24-07228" ref-type="bibr">84</xref>]. Apart from a rise in global awareness of the subject of ASD and a more inclusive definition in the Diagnostic and Statistical Manual of Mental Disorders V (DSM V) [<xref rid="B85-ijms-24-07228" ref-type="bibr">85</xref>], a real increase in ASD&#x02019;s prevalence is being suggested. In 2014, Nevison [<xref rid="B84-ijms-24-07228" ref-type="bibr">84</xref>] stated that in the United States since 1988, a real increase in ASD prevalence accounts for circa 75&#x02013;80% of the tracked increase in its diagnosis. </p><p>The pathogenesis of ASD is not fully elucidated [<xref rid="B86-ijms-24-07228" ref-type="bibr">86</xref>]. Suspected risk factors of ASD are genetic factors, advanced parental age, prenatal infections, and exposure to toxic substances [<xref rid="B83-ijms-24-07228" ref-type="bibr">83</xref>,<xref rid="B85-ijms-24-07228" ref-type="bibr">85</xref>], among which some authors mention Al [<xref rid="B87-ijms-24-07228" ref-type="bibr">87</xref>,<xref rid="B88-ijms-24-07228" ref-type="bibr">88</xref>,<xref rid="B89-ijms-24-07228" ref-type="bibr">89</xref>]. Noteworthy, over 1000 various substances were considered neurotoxic in laboratory studies, of which over 200 have been documented as neurotoxic in humans [<xref rid="B90-ijms-24-07228" ref-type="bibr">90</xref>]. In USA population, exposure to some factors considered as risk factors of ASD represent constant (e.g., phthalates, atmospheric mercury (Hg)) or decreasing trends (e.g., lead (Pb), dioxins, vehicular emission), making them less likely to be involved in ASD prevalence in the USA [<xref rid="B84-ijms-24-07228" ref-type="bibr">84</xref>]. </p><p>To investigate the link between ASD and exposure to several metals, including Al, Sulaiman et al. [<xref rid="B85-ijms-24-07228" ref-type="bibr">85</xref>] in 2020 published meta-analysis comprising case-control and cross-sectional studies. Apart from individual studies showing inconsistent results, the meta-analysis found that Al concentration in both hair and urine samples was positively correlated with ASD, while Al concentration in blood was negatively associated with ASD. Thus, a suggestion was made that ASD is presumably associated with impaired abilities of certain metal metabolism, detoxification, and excretion. Those authors supported the efforts to reduce lifespan exposure to neurotoxic metals, particularly in pregnant women and young children who are the most susceptible to their effects [<xref rid="B85-ijms-24-07228" ref-type="bibr">85</xref>]. In 2022, Amadi et al. [<xref rid="B86-ijms-24-07228" ref-type="bibr">86</xref>] published a meta-analysis of case-control studies on several toxic metal burdens in ASD patients. The results confirmed excessive toxic metal concentration in ASD patients [<xref rid="B86-ijms-24-07228" ref-type="bibr">86</xref>]. The evidence of Al concentration in ASD sufferers&#x02019; brains is limited [<xref rid="B86-ijms-24-07228" ref-type="bibr">86</xref>]. The first study conducted among 10 ASD donors&#x02019; brains reported elevated Al concentration with an intracellular and extracellular space (<xref rid="ijms-24-07228-t004" ref-type="table">Table 4</xref>) [<xref rid="B76-ijms-24-07228" ref-type="bibr">76</xref>]. However, McLachlan et al. [<xref rid="B64-ijms-24-07228" ref-type="bibr">64</xref>] found no association was found between ASD and Al concentration in temporal gyri (<xref rid="ijms-24-07228-t004" ref-type="table">Table 4</xref>). </p><p>Among the sources of Al in infants, milk formulas, intravenous feeding solutions, and possibly Al-containing vaccine adjuvants are suggested [<xref rid="B8-ijms-24-07228" ref-type="bibr">8</xref>]. However, the association between Al-containing adjuvants and ASD is highly controversial [<xref rid="B91-ijms-24-07228" ref-type="bibr">91</xref>], as Al adjuvants are linked with minimal adverse effects [<xref rid="B92-ijms-24-07228" ref-type="bibr">92</xref>,<xref rid="B93-ijms-24-07228" ref-type="bibr">93</xref>]. In research by Mitkus et al. [<xref rid="B94-ijms-24-07228" ref-type="bibr">94</xref>], Al diet and vaccine exposure during the first year of life did not exceed the minimal risk levels specified by ATSDR [<xref rid="B95-ijms-24-07228" ref-type="bibr">95</xref>]. Additionally, no link between blood and hair Al and the history of immunization by Karwowski et al. [<xref rid="B96-ijms-24-07228" ref-type="bibr">96</xref>] in a group of 85 healthy infants aged 9&#x02013;13 months. However, authors of several studies emphasize the role of prospective epidemiological studies [<xref rid="B91-ijms-24-07228" ref-type="bibr">91</xref>], with additional attention on exposure to metal [<xref rid="B97-ijms-24-07228" ref-type="bibr">97</xref>]. </p></sec><sec id="sec4-ijms-24-07228"><title>4. Alcohol Use Disorder</title><p>Alcohol Use Disorder (AUD) is a chronic and progressive disease that affects users&#x02019; daily functioning. AUD is caused by the loss of control over the amount of alcohol consumed and the continuous need for alcohol consumption [<xref rid="B98-ijms-24-07228" ref-type="bibr">98</xref>]. In AUD, Al accumulates in brain tissue, which can lead to dementia. This elevated Al accumulation can be caused by elevated permeability of the intestinal mucosa for Al, which is the result of excessive alcohol consumption [<xref rid="B99-ijms-24-07228" ref-type="bibr">99</xref>]. Additionally, despite the fact that Al contained in beer should be removed by properly functioning kidneys, this applies only to moderate beer consumption, which does not occur in AUD [<xref rid="B100-ijms-24-07228" ref-type="bibr">100</xref>]. </p><p>Another beer ingredient, Si, inhibits the negative impact of beer on the human brain: Si significantly affects the bioavailability of Al and may reduce its neurotoxicity [<xref rid="B101-ijms-24-07228" ref-type="bibr">101</xref>]. The hypothesis of the protective effect of Si was investigated in the research from 2004, which was carried out on mice. Mice were divided into three groups: the first group was given 2.5 mL commercial beer (5.5% volume) per week, the second group received 2.5 mL of silicic acid solution per week, and the third mice group received neither beer nor silicic acid. Next, after analysis, the levels of Al and Si in mice&#x02019;s urine, feces, and brain were found, and it was proved that Si content in beer reduced Al uptake and its accumulation in the brain [<xref rid="B102-ijms-24-07228" ref-type="bibr">102</xref>]. The other study also carried out on mice showed that Si contained in beer, the reason for the influence on Al toxicokinetics, can prevent inflammation and oxidative stress in the brain caused by Al [<xref rid="B103-ijms-24-07228" ref-type="bibr">103</xref>].</p><p>Moreover, exposure to Al can be a risk factor for AD and dementia development, while Si contained in beer can protect against these diseases by decreasing of uptake of Al from the digestive tract and inhibiting its accumulation [<xref rid="B104-ijms-24-07228" ref-type="bibr">104</xref>,<xref rid="B105-ijms-24-07228" ref-type="bibr">105</xref>]. </p><p>Beer not only affects Al bioavailability but also can reverse metal imbalance and pro-oxidative state that are caused by Al nitrate in the brain. In the study by Gonz&#x000e1;lez-Mu&#x000f1;oz et al. [<xref rid="B106-ijms-24-07228" ref-type="bibr">106</xref>], four groups of mice were studied: the first group was given deionized water, the second Al(NO<sub>3</sub>)<sub>3</sub>, the third Al(NO<sub>3</sub>)<sub>3</sub> and silicic acid, and the fourth Al(NO<sub>3</sub>)<sub>3</sub> and beer. As a result, in the third and the fourth group, a decrease in the concentrations of Al, Si, and thiobarbituric acid reactive substances (TBARS) and a decrease in the expression of TNF&#x003b1;, as well as an increase in the concentrations of copper (Cu), manganese (Mn), zinc (Zn), and antioxidants, compared to the second group. Those results suggested that Si reversed Al-induced influence to a significant extent [<xref rid="B106-ijms-24-07228" ref-type="bibr">106</xref>]. Another study also confirms that beer reduces the oxidation processes in the brain, which are caused by the toxicity of Al. In this research, mice were divided into two groups: the first group was given Al(NO<sub>3</sub>)<sub>3</sub> in drinking water, while the experimental mice were given Al(NO<sub>3</sub>)<sub>3</sub> in combination with silicic acid or beer. It was observed that beer inhibits the decrease in the mRNA expression of endogenous antioxidant enzymes, prevents damage of lipids, and normalizes the expression of TNF&#x003b1; [<xref rid="B107-ijms-24-07228" ref-type="bibr">107</xref>] (<xref rid="ijms-24-07228-t005" ref-type="table">Table 5</xref>). </p><p>These studies [<xref rid="B102-ijms-24-07228" ref-type="bibr">102</xref>,<xref rid="B103-ijms-24-07228" ref-type="bibr">103</xref>,<xref rid="B104-ijms-24-07228" ref-type="bibr">104</xref>,<xref rid="B105-ijms-24-07228" ref-type="bibr">105</xref>,<xref rid="B106-ijms-24-07228" ref-type="bibr">106</xref>,<xref rid="B107-ijms-24-07228" ref-type="bibr">107</xref>] refer to moderate alcohol consumption. In AUD, alcohol is consumed excessively. The concentration of Al and Si in the brain and liver of individuals with AUD was examined in a study from 2019. Brain and liver samples were collected in post-mortem examination from 31 patients with AUD and 32 patients without AUD as the control group. The study showed that AUD patients had elevated concentrations of Al in the brain (see <xref rid="ijms-24-07228-t004" ref-type="table">Table 4</xref>). Moreover, the highest concentration of Al was detected in the frontal part of the thalamus, inferior longitudinal fasciculus, and frontal part of the insula. However, a higher concentration of Si was not observed in the brain of AUD patients, which suggests, that excessive consumption of alcohol results in significantly increased exposure to Al, but more studies are needed to investigate this in depth [<xref rid="B77-ijms-24-07228" ref-type="bibr">77</xref>]. </p></sec><sec id="sec5-ijms-24-07228"><title>5. Multiple Sclerosis</title><p>MS is a chronic, autoimmunological disease causing demyelination of CNS. As its pathogenesis remains unclear, the search for its trigger factors remains a significant challenge in neurology [<xref rid="B111-ijms-24-07228" ref-type="bibr">111</xref>]. Nowadays, exposure to Al is identified as a trigger factor. The study from 2018 carried out on brain tissue from 14 patients with MS revealed higher Al levels in both intracellular and extracellular locations [<xref rid="B112-ijms-24-07228" ref-type="bibr">112</xref>]. In another study, to further show how high the concentration of Al is in the brain tissue of individuals with MS, Linhart et al. [<xref rid="B113-ijms-24-07228" ref-type="bibr">113</xref>] compared the concentration of Al in the brains of MS patients with the control group of brains from non-MS patients. Although Al was detected in each donor, comparing Al concentrations proved that donors dying with a diagnosis of MS presented elevated Al concentrations [<xref rid="B113-ijms-24-07228" ref-type="bibr">113</xref>]. Similar results were obtained by Exley et al. [<xref rid="B78-ijms-24-07228" ref-type="bibr">78</xref>], whose study also suggests that the concentration of Al is significantly higher in the brain tissue compared to the control group of patients without several neurological diseases (AD, MS, and ASD&#x02014;see <xref rid="ijms-24-07228-t004" ref-type="table">Table 4</xref>) [<xref rid="B78-ijms-24-07228" ref-type="bibr">78</xref>]. Another study pointed to the potential role of metabolic imbalance of Al in MS development: the concentration of Al in the scalp hair of patients with MS and healthy controls were examined. Results showed that the scalp hair Al concentration of MS patients was significantly lower, which can be caused by its accumulation in brain tissue and significant urinary excretion [<xref rid="B79-ijms-24-07228" ref-type="bibr">79</xref>]. </p><p>Patients with MS not only presented a high concentration of Al in brain tissue but also in the urine. Moreover, the concentration of Al excretion in individuals with MS was similar to those observed in patients undergoing metal chelation therapy [<xref rid="B80-ijms-24-07228" ref-type="bibr">80</xref>]. Al excretion with urine seems of use in the non-invasive treatment of MS: therapy by Si-rich mineral water. In the study from 2017, carried out on a group of 15 patients with MS, the following regime was used: patients drank 1.5 L Si-rich mineral water daily per 12 weeks, which resulted in the increase of Al urinary excretion, which may consequently add to the reduction of its accumulation in the body, including the brain [<xref rid="B114-ijms-24-07228" ref-type="bibr">114</xref>]. </p><p>A link between exposure to Al and MS development gave rise to the inclusion of ethylenediaminetetraacetic acid (EDTA) chelation therapy in the treatment. The study from 2014 examined a group of patients with neurological disease; 85.6% (n = 101) of them had MS and a healthy control group. All patients were challenged with EDTA, and those who showed Al poisoning after this test were subjected to chelation therapy (EDTA iv once a week). The use of EDTA proved effective in removing excess Al. Additionally, shortening the duration of Al intoxication resulted in a significant improvement in the clinical condition of patients: there was a reduction in neurological disability and fatigue [<xref rid="B115-ijms-24-07228" ref-type="bibr">115</xref>]. Fulgenzi et al. [<xref rid="B116-ijms-24-07228" ref-type="bibr">116</xref>] described a case of a patient with MS treated by EDTA. After the challenge with EDTA, the level of Al in the patient&#x02019;s urine was elevated. Next, the patient was treated by EDTA, and as a result, neurological condition improvement and remission of MS were all observed; additionally, the level of Al in the urine decreased to normal values [<xref rid="B116-ijms-24-07228" ref-type="bibr">116</xref>].</p></sec><sec id="sec6-ijms-24-07228"><title>6. Parkinson&#x02019;s Disease</title><p>PD is a progressive neurodegenerative disorder manifested by motor symptoms such as slowness of movement, tremors, stiffness, postural instability, and non-motor symptoms: depression, anxiety, dementia, and autonomic dysfunction. The ultimate cause of PD is unknown, but studies point to risk factors such as age, family history, and pesticide exposure [<xref rid="B117-ijms-24-07228" ref-type="bibr">117</xref>,<xref rid="B118-ijms-24-07228" ref-type="bibr">118</xref>]. Additionally, long-term exposure to Al creates a risk factor for PD. Al accumulates in the substantia nigra and in Lewy bodies and disrupts the dopaminergic system by affecting the activity of the enzyme involved in the dopamine (DA) biosynthesis pathway [<xref rid="B119-ijms-24-07228" ref-type="bibr">119</xref>,<xref rid="B120-ijms-24-07228" ref-type="bibr">120</xref>]. Additionally, the research carried out on zebrafish showed that exposure to Al not only causes neurodegenerative processes but also influences the regulation of genes related to PD [<xref rid="B2-ijms-24-07228" ref-type="bibr">2</xref>]. </p><p>The main sources of Al are occupational exposure and environmental pollution. Occupational exposure to Al doubles the risk of PD [<xref rid="B87-ijms-24-07228" ref-type="bibr">87</xref>]. Occupational exposure to Al as a risk factor for PD has been described in studies by Zeng et al. [<xref rid="B121-ijms-24-07228" ref-type="bibr">121</xref>]. This retrospective study was conducted on a cohort of 37,000 male miners in Ontario and found that miners with respiratory exposure to Al had a 30% higher incidence of PD [<xref rid="B121-ijms-24-07228" ref-type="bibr">121</xref>]. Moreover, the higher risk of PD seems to be correlated with the duration of exposure to Al. Additionally, the study by Martell et al. [<xref rid="B122-ijms-24-07228" ref-type="bibr">122</xref>] showed that miners exposed to inhalation of finely ground Al dust had a significantly higher risk of developing PD compared to unexposed miners or the Ontario population [<xref rid="B122-ijms-24-07228" ref-type="bibr">122</xref>]. It was ascertained that the combined exposure to Al and other metals increases their toxic effect on the &#x02013;NS-Hg and has a synergistic effect with Al. The combination of Mn, Fe, and Al has been significantly associated with a higher risk of PD [<xref rid="B123-ijms-24-07228" ref-type="bibr">123</xref>]. A similar relationship is exhibited between Al and pesticides: they accelerate the rate of formation of alpha-synuclein fibrils [<xref rid="B124-ijms-24-07228" ref-type="bibr">124</xref>]. According to the study by Altschuler [<xref rid="B125-ijms-24-07228" ref-type="bibr">125</xref>], another source of Al is constituted by Al-containing antacids which may be involved in PD development. Patients with peptic ulcer disease not only had an increased absorption of Al but also relied on Al-containing antacids [<xref rid="B125-ijms-24-07228" ref-type="bibr">125</xref>]. </p><p>The examination of the level of Al in the serum seems to be a valuable method in the diagnosis of early PD. An analysis of the level of Al in combination with disturbance in the elements&#x02019; homeostasis and inter-elements relationship by the neural-network algorithm can be a valuable method of early PD diagnosis: use of an artificial neuronal network (ANN) algorithm provides 95% accuracy [<xref rid="B126-ijms-24-07228" ref-type="bibr">126</xref>]. Additionally, due to the role of Al in PD development, inhibition of its activity seems to be a therapeutic target. Al-induced neurodegeneration in PD can be restricted by the natural flavonoid&#x02014;Quercetin. A study from 2016 conducted on rats showed that quercetin, used in the mechanism of reduction of Al-induced oxidative stress, largely inhibits neuronal apoptosis. For this reason, quercetin presents potential therapeutic value in slowing down the progression of PD [<xref rid="B108-ijms-24-07228" ref-type="bibr">108</xref>] (<xref rid="ijms-24-07228-t005" ref-type="table">Table 5</xref>). The other substance, curcumin, also seems to be useful in protecting the brain from Al-inducted neurotoxicity. The research carried out on rats showed that it inhibits disruption of the dopaminergic system in PD as a result of the normalization of activity of the tyrosine hydroxylase (TH), an enzyme involved in the dopamine biosynthesis pathway [<xref rid="B109-ijms-24-07228" ref-type="bibr">109</xref>] (<xref rid="ijms-24-07228-t005" ref-type="table">Table 5</xref>). The study from 2022 suggests that Centella Asiatica affects oxidative stress in the brain, inhibits neurodegeneration caused by Al, and presents potential therapeutic value in preventing Al-inducted PD [<xref rid="B110-ijms-24-07228" ref-type="bibr">110</xref>] (<xref rid="ijms-24-07228-t005" ref-type="table">Table 5</xref>).</p></sec><sec id="sec7-ijms-24-07228"><title>7. Dialysis Encephalopathy</title><p>DE is a progressive, fatal disease linked to Al toxicity in CNS. Clinical manifestations of DE include dementia; language dysfunctions, such as slurred speech, stuttering, the problem with forming accurate phrases, permanent mutism, and aphasia; motor function damage, including myoclonus, epilepsy, tremor, flapping wing tremor, grimace, abnormal gait, athetosis, rigidity, and weakness; mental and behavioral disorders [<xref rid="B127-ijms-24-07228" ref-type="bibr">127</xref>]. The main source of Al in DE is the water used to prepare dialysis fluid [<xref rid="B128-ijms-24-07228" ref-type="bibr">128</xref>] and Al-containing phosphate binders, which were used for the prevention of hyperphosphataemia [<xref rid="B129-ijms-24-07228" ref-type="bibr">129</xref>,<xref rid="B130-ijms-24-07228" ref-type="bibr">130</xref>]. </p><p>Al in DE accumulates in the brain, which can be observed in the postmortal examination. The study by McDermott et al. [<xref rid="B81-ijms-24-07228" ref-type="bibr">81</xref>] of postmortal brain examination showed that the concentration of Al was elevated in some patients who deceased due to dialysis encephalopathy compared to the control group of dialysis and non-dialysis patients with uremia. Al accumulated mainly in the grey matter of patients&#x02019; brains. Moreover, the Al concentration in the patient&#x02019;s brain remains elevated for up to four years after kidney transplantation [<xref rid="B81-ijms-24-07228" ref-type="bibr">81</xref>]. Similar results were obtained by Alfrey et al. [<xref rid="B82-ijms-24-07228" ref-type="bibr">82</xref>], who examined the concentration of Al in muscles, bones, and brains of uremic patients on dialysis. The study showed that the concentration of muscle and bone Al was higher as compared to the concentration in the control group. Additionally, the concentration of Al in the grey matter of the brain of patients with DE was higher compared to any of the control subjects or other uremic patients on dialysis [<xref rid="B82-ijms-24-07228" ref-type="bibr">82</xref>]. Al accumulates in the neutrons and astrocytes of the cerebral cortex. The autopsy of three brains of patients who died of DE showed spongy lesions limited to the upper layers of the cerebral cortex, which contained vacuoles inside the neuropil and nerve cell bodies [<xref rid="B131-ijms-24-07228" ref-type="bibr">131</xref>]. </p><p>To reduce the risk of DE in patients with chronic kidney disease, reduction of exposure to Al is indispensable. Results of a study from 1980 showed that cleaning the dialysis fluid with a water softener, reverse osmosis, and deionizer can significantly reduce the development of DE incidence. Previously, seven patients had died of DE, and 16 of the 51 surviving patients had symptoms of DE. [<xref rid="B132-ijms-24-07228" ref-type="bibr">132</xref>]. Additionally, some authors suggested that avoidance of Al-based phosphate binders and chelation agent treatments seem to be promising methods in the prevention of DE [<xref rid="B133-ijms-24-07228" ref-type="bibr">133</xref>]. DFO is the chelation agent used in the Al intoxication of dialysis patients, which can also be used as a noninvasive method of identification of dialysis with Al overload. [<xref rid="B134-ijms-24-07228" ref-type="bibr">134</xref>]. The combined use of DFO and hemodialysis was described as a good method of treatment for patients with severe Al encephalopathy. On the other hand, DFO cannot always be used in DE treatment: the high concentration of Al in serum after treatment with DFO induces the concentrations of toxic DFO-Al complexes and causes to worsen the condition of the patient. For this reason, at serum Al concentrations higher than 200 &#x003bc;g/L, DFO is not recommended for treatment [<xref rid="B127-ijms-24-07228" ref-type="bibr">127</xref>,<xref rid="B135-ijms-24-07228" ref-type="bibr">135</xref>].</p></sec><sec sec-type="conclusions" id="sec8-ijms-24-07228"><title>8. Conclusions</title><p>The main source of exposure to Al is oral ingestion and inhalation, whereas the primary way of Al excretion is through urine. The literature clearly suggests that AD, AUD, MS, PD, and DE patients experience excessive accumulation of Al in the CNS. Epidemiological links between higher exposure to Al and their increased incidence have been observed in AD, PD, and DE. In AD and PD, the potential use of Al as a disease marker has been noted. Additionally, favorable results of the use of Al chelators were observed in AD, AUD, MS, and DE. Moreover, cleaning dialysis fluid from Al prevents the development of DE. The risk of Al toxicity via vaccination is minimal compared to the benefits presented by vaccinations alone, and data regarding skin Al absorption appear to be limited.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.B. and &#x00141;.B.; methodology, K.K. and F.W.; investigation, P.D.; writing&#x02014;original draft preparation, &#x00141;.B., K.K., F.W., P.D., J.G., M.G., and R.S.; writing&#x02014;review and editing, J.B. and J.F.; supervision, G.T.; funding acquisition, G.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AChE</td><td align="left" valign="middle" rowspan="1" colspan="1">Acetylcholinesterase </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AD</td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimer&#x02019;s disease </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Al</td><td align="left" valign="middle" rowspan="1" colspan="1">Aluminium </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALS</td><td align="left" valign="middle" rowspan="1" colspan="1">Amyotrophic lateral sclerosis </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ANN</td><td align="left" valign="middle" rowspan="1" colspan="1">Artificial neuronal network </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ASD</td><td align="left" valign="middle" rowspan="1" colspan="1">Autism spectrum disorder </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATSDR</td><td align="left" valign="middle" rowspan="1" colspan="1">Agency for Toxic Substances and Disease Registry </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AUD</td><td align="left" valign="middle" rowspan="1" colspan="1">Alcohol use disorder </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bax</td><td align="left" valign="middle" rowspan="1" colspan="1">Bcl-2-associated X protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BBB</td><td align="left" valign="middle" rowspan="1" colspan="1">Blood-brain barrier </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bcl-2</td><td align="left" valign="middle" rowspan="1" colspan="1">B-cell lymphoma 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BMP-2</td><td align="left" valign="middle" rowspan="1" colspan="1">Bone morphogenic protein 2 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bw</td><td align="left" valign="middle" rowspan="1" colspan="1">Body weight</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAE</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethanolic extract of <italic toggle="yes">Centella asiatica</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cal/OSHA</td><td align="left" valign="middle" rowspan="1" colspan="1">California&#x02019;s Division of Occupational Safety and Health</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAT</td><td align="left" valign="middle" rowspan="1" colspan="1">Catalase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Criteria chronic concentration;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Criteria maximum concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Cerebro-spinal fluid </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSN</td><td align="left" valign="middle" rowspan="1" colspan="1">Central nervous system</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cu</td><td align="left" valign="middle" rowspan="1" colspan="1">Copper </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CuZnSOD</td><td align="left" valign="middle" rowspan="1" colspan="1">Copper-zinc SOD</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cyt c</td><td align="left" valign="middle" rowspan="1" colspan="1">cytochrome c</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DA</td><td align="left" valign="middle" rowspan="1" colspan="1">Dopamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Daergic</td><td align="left" valign="middle" rowspan="1" colspan="1">dopaminergic</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DE</td><td align="left" valign="middle" rowspan="1" colspan="1">Dialysis encephalopathy </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DFO</td><td align="left" valign="middle" rowspan="1" colspan="1">Deferoxamine </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EDTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethylenediaminetetraacetic acid </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EFSA</td><td align="left" valign="middle" rowspan="1" colspan="1">European Food Safety Authority</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EPA</td><td align="left" valign="middle" rowspan="1" colspan="1">Environmental Protection Agency</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Fe</td><td align="left" valign="middle" rowspan="1" colspan="1">Iron </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPx</td><td align="left" valign="middle" rowspan="1" colspan="1">glutathione peroxidase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hg</td><td align="left" valign="middle" rowspan="1" colspan="1">Mercury </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LOAEL</td><td align="left" valign="middle" rowspan="1" colspan="1">Lowest-observed-adverse-effect level</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Malondialdehyde</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mn</td><td align="left" valign="middle" rowspan="1" colspan="1">Manganese </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MnSOD</td><td align="left" valign="middle" rowspan="1" colspan="1">Manganese SOD</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MS</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple sclerosis </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NFTs</td><td align="left" valign="middle" rowspan="1" colspan="1">Neurofibrillary tangles </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NIOSH</td><td align="left" valign="middle" rowspan="1" colspan="1">The National Institute for Occupational Safety and Health</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOAEL</td><td align="left" valign="middle" rowspan="1" colspan="1">No-observed-adverse-effect level</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NOS</td><td align="left" valign="middle" rowspan="1" colspan="1">Not otherwise specified</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OSHA</td><td align="left" valign="middle" rowspan="1" colspan="1">Occupational Safety and Health Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">p53</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor protein 53</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pb</td><td align="left" valign="middle" rowspan="1" colspan="1">Lead </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD</td><td align="left" valign="middle" rowspan="1" colspan="1">Parkinson&#x02019;s disease </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PEL</td><td align="left" valign="middle" rowspan="1" colspan="1">Permissible exposure limit</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PTWI</td><td align="left" valign="middle" rowspan="1" colspan="1">provisional tolerable weekly intake</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">REL</td><td align="left" valign="middle" rowspan="1" colspan="1">recommended exposure limit</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCCS</td><td align="left" valign="middle" rowspan="1" colspan="1">Scientific Committee on Consumer Safety </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCHEER</td><td align="left" valign="middle" rowspan="1" colspan="1">Scientific Committee on Health, Environmental and Emerging Risks</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Si</td><td align="left" valign="middle" rowspan="1" colspan="1">Silicon </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNc</td><td align="left" valign="middle" rowspan="1" colspan="1">Substantia nigra pars compact </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SOD</td><td align="left" valign="middle" rowspan="1" colspan="1">Superoxide dismutase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TBARS</td><td align="left" valign="middle" rowspan="1" colspan="1">Thiobarbituric acid reactive substances</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tf</td><td align="left" valign="middle" rowspan="1" colspan="1">Transferrin </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TfR</td><td align="left" valign="middle" rowspan="1" colspan="1">Transferrin receptor </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#x0a7b5;1</td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming grow factor beta 1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TH</td><td align="left" valign="middle" rowspan="1" colspan="1">Tyrosine hydroxylase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TWA</td><td align="left" valign="middle" rowspan="1" colspan="1">Time weighted average</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TWI</td><td align="left" valign="middle" rowspan="1" colspan="1">Tolerable weekly intake</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ventral tegmental area</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO</td><td align="left" valign="middle" rowspan="1" colspan="1">World Health Organization</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Zn</td><td align="left" valign="middle" rowspan="1" colspan="1">Zinc</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-ijms-24-07228"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Ingerman</surname><given-names>L.</given-names></name>
<name><surname>Jones</surname><given-names>D.G.</given-names></name>
<name><surname>Keith</surname><given-names>S.</given-names></name>
<name><surname>Rosemond</surname><given-names>Z.A.</given-names></name>
</person-group><article-title>ATSDR Toxicological Profile for Aluminum</article-title><source>ATSDR&#x02019;s Toxicological Profiles</source><publisher-name>ATSDR</publisher-name><publisher-loc>Atlanta, GA, USA</publisher-loc><year>2008</year></element-citation></ref><ref id="B2-ijms-24-07228"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capriello</surname><given-names>T.</given-names></name>
<name><surname>Di Meglio</surname><given-names>G.</given-names></name>
<name><surname>De Maio</surname><given-names>A.</given-names></name>
<name><surname>Scudiero</surname><given-names>R.</given-names></name>
<name><surname>Bianchi</surname><given-names>A.R.</given-names></name>
<name><surname>Trifuoggi</surname><given-names>M.</given-names></name>
<name><surname>Toscanesi</surname><given-names>M.</given-names></name>
<name><surname>Giarra</surname><given-names>A.</given-names></name>
<name><surname>Ferrandino</surname><given-names>I.</given-names></name>
</person-group><article-title>Aluminium Exposure Leads to Neurodegeneration and Alters the Expression of Marker Genes Involved to Parkinsonism in Zebrafish Brain</article-title><source>Chemosphere</source><year>2022</year><volume>307</volume><fpage>135752</fpage><pub-id pub-id-type="doi">10.1016/j.chemosphere.2022.135752</pub-id><pub-id pub-id-type="pmid">35863414</pub-id></element-citation></ref><ref id="B3-ijms-24-07228"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exley</surname><given-names>C.</given-names></name>
<name><surname>House</surname><given-names>E.R.</given-names></name>
</person-group><article-title>Aluminium in the Human Brain</article-title><source>Mon. Chem.</source><year>2011</year><volume>142</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1007/s00706-010-0417-y</pub-id></element-citation></ref><ref id="B4-ijms-24-07228"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Igbokwe</surname><given-names>I.O.</given-names></name>
<name><surname>Igwenagu</surname><given-names>E.</given-names></name>
<name><surname>Igbokwe</surname><given-names>N.A.</given-names></name>
</person-group><article-title>Aluminium Toxicosis: A Review of Toxic Actions and Effects</article-title><source>Interdiscip. Toxicol.</source><year>2019</year><volume>12</volume><fpage>45</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.2478/intox-2019-0007</pub-id><pub-id pub-id-type="pmid">32206026</pub-id></element-citation></ref><ref id="B5-ijms-24-07228"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inan-Eroglu</surname><given-names>E.</given-names></name>
<name><surname>Ayaz</surname><given-names>A.</given-names></name>
</person-group><article-title>Is Aluminum Exposure a Risk Factor for Neurological Disorders?</article-title><source>J. Res. Med. Sci.</source><year>2018</year><volume>23</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.4103/JRMS.JRMS_921_17</pub-id><pub-id pub-id-type="pmid">30057635</pub-id></element-citation></ref><ref id="B6-ijms-24-07228"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Human Exposure to Aluminium</article-title><source>Environ. Sci. Process. Impacts</source><year>2013</year><volume>15</volume><fpage>1807</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1039/C3EM00374D</pub-id><pub-id pub-id-type="pmid">23982047</pub-id></element-citation></ref><ref id="B7-ijms-24-07228"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Overview of the Relationship between Aluminum Exposure and Health of Human Being</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1091</volume><fpage>1</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">30315446</pub-id></element-citation></ref><ref id="B8-ijms-24-07228"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alasfar</surname><given-names>R.H.</given-names></name>
<name><surname>Isaifan</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Aluminum Environmental Pollution: The Silent Killer</article-title><source>Environ. Sci. Pollut. Res. Int.</source><year>2021</year><volume>28</volume><fpage>44587</fpage><lpage>44597</lpage><pub-id pub-id-type="doi">10.1007/s11356-021-14700-0</pub-id><pub-id pub-id-type="pmid">34196863</pub-id></element-citation></ref><ref id="B9-ijms-24-07228"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krupi&#x00144;ska</surname><given-names>I.</given-names></name>
</person-group><article-title>Aluminium Drinking Water Treatment Residuals and Their Toxic Impact on Human Health</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>641</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25030641</pub-id><pub-id pub-id-type="pmid">32024220</pub-id></element-citation></ref><ref id="B10-ijms-24-07228"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crisponi</surname><given-names>G.</given-names></name>
<name><surname>Fanni</surname><given-names>D.</given-names></name>
<name><surname>Gerosa</surname><given-names>C.</given-names></name>
<name><surname>Nemolato</surname><given-names>S.</given-names></name>
<name><surname>Nurchi</surname><given-names>V.M.</given-names></name>
<name><surname>Crespo-Alonso</surname><given-names>M.</given-names></name>
<name><surname>Lachowicz</surname><given-names>J.I.</given-names></name>
<name><surname>Faa</surname><given-names>G.</given-names></name>
</person-group><article-title>The Meaning of Aluminium Exposure on Human Health and Aluminium-Related Diseases</article-title><source>Biomol. Concepts</source><year>2013</year><volume>4</volume><fpage>77</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1515/bmc-2012-0045</pub-id><pub-id pub-id-type="pmid">25436567</pub-id></element-citation></ref><ref id="B11-ijms-24-07228"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Riihim&#x000e4;ki</surname><given-names>V.</given-names></name>
<name><surname>Aitio</surname><given-names>A.</given-names></name>
</person-group><article-title>Occupational Exposure to Aluminum and Its Biomonitoring in Perspective</article-title><source>Crit. Rev. Toxicol.</source><year>2012</year><volume>42</volume><fpage>827</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.3109/10408444.2012.725027</pub-id><pub-id pub-id-type="pmid">23013241</pub-id></element-citation></ref><ref id="B12-ijms-24-07228"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tietz</surname><given-names>T.</given-names></name>
<name><surname>Lenzner</surname><given-names>A.</given-names></name>
<name><surname>Kolbaum</surname><given-names>A.E.</given-names></name>
<name><surname>Zellmer</surname><given-names>S.</given-names></name>
<name><surname>Riebeling</surname><given-names>C.</given-names></name>
<name><surname>G&#x000fc;rtler</surname><given-names>R.</given-names></name>
<name><surname>Jung</surname><given-names>C.</given-names></name>
<name><surname>Kappenstein</surname><given-names>O.</given-names></name>
<name><surname>Tentschert</surname><given-names>J.</given-names></name>
<name><surname>Giulbudagian</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Aggregated Aluminium Exposure: Risk Assessment for the General Population</article-title><source>Arch. Toxicol.</source><year>2019</year><volume>93</volume><fpage>3503</fpage><lpage>3521</lpage><pub-id pub-id-type="doi">10.1007/s00204-019-02599-z</pub-id><pub-id pub-id-type="pmid">31659427</pub-id></element-citation></ref><ref id="B13-ijms-24-07228"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paz</surname><given-names>S.</given-names></name>
</person-group><article-title>Aluminium Exposure Through the Diet</article-title><source>Food Sci. Nutr.</source><year>2017</year><volume>3</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.24966/FSN-1076/100020</pub-id></element-citation></ref><ref id="B14-ijms-24-07228"><label>14.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>United States Department of Labor, Occupational Safety and Health Administration Webpage</collab>
</person-group><article-title>Permissible Exposure Limits&#x02014;OSHA Annotated Table Z-1</article-title><comment>Available online: <ext-link xlink:href="https://www.osha.gov/annotated-pels/table-z-1" ext-link-type="uri">https://www.osha.gov/annotated-pels/table-z-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-11">(accessed on 11 March 2023)</date-in-citation></element-citation></ref><ref id="B15-ijms-24-07228"><label>15.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>California Division of Occupational Safety and Health Webpage</collab>
</person-group><article-title>Permissible Exposure Limits for Chemical Contaminants Table AC-1</article-title><comment>Available online: <ext-link xlink:href="http://www.dir.ca.gov/title8/5155table_ac1.html" ext-link-type="uri">http://www.dir.ca.gov/title8/5155table_ac1.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-11">(accessed on 11 March 2023)</date-in-citation></element-citation></ref><ref id="B16-ijms-24-07228"><label>16.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (CDC), The National Institute for Occupational Safety and Health (NIOSH) Webpage</collab>
</person-group><article-title>NIOSH Pocket Guide to Chemical Hazards&#x02014;Aluminum</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/niosh/npg/npgd0022.html#print" ext-link-type="uri">https://www.cdc.gov/niosh/npg/npgd0022.html#print</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-09">(accessed on 9 March 2023)</date-in-citation></element-citation></ref><ref id="B17-ijms-24-07228"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>European Food Safety Authority (EFSA)</collab>
</person-group><article-title>Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Food Contact Materials on a Request from European Commission on Safety of Aluminium from Dietary Intake</article-title><source>EFSA J.</source><year>2008</year><volume>754</volume><fpage>1</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2903/J.EFSA.2008.754</pub-id></element-citation></ref><ref id="B18-ijms-24-07228"><label>18.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organisation</collab>
<collab>Food and Agriculture Organization of the United Nations &#x00026; Joint FAO/WHO Expert Committee on Food Additives</collab>
</person-group><article-title>Meeting (74th: 2011: Rome, I. (2011). Evaluation of Certain Food Additives and Contaminants: Seventy-Fourth [74th] Report of the Joint FAO/WHO Expert Committee on Food Additives</article-title><comment>Available online: <ext-link xlink:href="https://apps.who.int/iris/handle/10665/44788" ext-link-type="uri">https://apps.who.int/iris/handle/10665/44788</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-12">(accessed on 12 March 2023)</date-in-citation></element-citation></ref><ref id="B19-ijms-24-07228"><label>19.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organisation World Health Organization</collab>
</person-group><article-title>Aluminium in Drinking-Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality. World Health Organization</article-title><year>2003</year><comment>Available online: <ext-link xlink:href="https://apps.who.int/iris/handle/10665/75362" ext-link-type="uri">https://apps.who.int/iris/handle/10665/75362</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-12">(accessed on 12 March 2023)</date-in-citation></element-citation></ref><ref id="B20-ijms-24-07228"><label>20.</label><element-citation publication-type="gov"><article-title>United States Environmental Protection Agency Webpage, Drinking Water Regulations and Contaminants</article-title><comment>Available online: <ext-link xlink:href="https://www.epa.gov/sdwa/drinking-water-regulations-and-contaminants#List" ext-link-type="uri">https://www.epa.gov/sdwa/drinking-water-regulations-and-contaminants#List</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-03-11">(accessed on 11 March 2023)</date-in-citation></element-citation></ref><ref id="B21-ijms-24-07228"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wildeman</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Final Aquatic Life Criteria for Aluminum in Freshwater</article-title><source>Fed. Regist.</source><year>2018</year><volume>83</volume><fpage>65663</fpage><lpage>65665</lpage></element-citation></ref><ref id="B22-ijms-24-07228"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>European Commission</collab>
<collab>Directorate-General for Health and Food Safety</collab>
</person-group><source>Final Opinion on Tolerable Intake of Aluminium with Regards to Adapting the Migration Limits for Aluminium in Toys</source><publisher-name>European Commission</publisher-name><publisher-loc>Brussels, Belgium</publisher-loc><year>2018</year><pub-id pub-id-type="doi">10.2875/264211</pub-id></element-citation></ref><ref id="B23-ijms-24-07228"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saiyed</surname><given-names>S.M.</given-names></name>
<name><surname>Yokel</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Aluminium Content of Some Foods and Food Products in the USA, with Aluminium Food Additives</article-title><source>Food Addit. Contam.</source><year>2005</year><volume>22</volume><fpage>234</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1080/02652030500073584</pub-id><pub-id pub-id-type="pmid">16019791</pub-id></element-citation></ref><ref id="B24-ijms-24-07228"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>T.</given-names></name>
<name><surname>Taschan</surname><given-names>H.</given-names></name>
<name><surname>Brunn</surname><given-names>H.</given-names></name>
</person-group><article-title>Aluminium Content of Selected Foods and Food Products</article-title><source>Environ. Sci. Eur.</source><year>2011</year><volume>23</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/2190-4715-23-37</pub-id></element-citation></ref><ref id="B25-ijms-24-07228"><label>25.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><source>Guidelines for Drinking-Water Quality: Fourth Edition Incorporating the First Addendum</source><publisher-name>WHO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2017</year></element-citation></ref><ref id="B26-ijms-24-07228"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reinke</surname><given-names>C.M.</given-names></name>
<name><surname>Breitkreutz</surname><given-names>J.</given-names></name>
<name><surname>Leuenberger</surname><given-names>H.</given-names></name>
</person-group><article-title>Aluminium in Over-the-Counter Drugs: Risks Outweigh Benefits?</article-title><source>Drug Saf.</source><year>2003</year><volume>26</volume><fpage>1011</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.2165/00002018-200326140-00003</pub-id><pub-id pub-id-type="pmid">14583063</pub-id></element-citation></ref><ref id="B27-ijms-24-07228"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weberg</surname><given-names>R.</given-names></name>
<name><surname>Berstad</surname><given-names>A.</given-names></name>
</person-group><article-title>Gastrointestinal Absorption of Aluminium from Single Doses of Aluminium Containing Antacids in Man</article-title><source>Eur. J. Clin. Investig.</source><year>1986</year><volume>16</volume><fpage>428</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1111/J.1365-2362.1986.TB01018.X</pub-id><pub-id pub-id-type="pmid">3100311</pub-id></element-citation></ref><ref id="B28-ijms-24-07228"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanajou</surname><given-names>S.</given-names></name>
<name><surname>&#x0015e;ahin</surname><given-names>G.</given-names></name>
<name><surname>Baydar</surname><given-names>T.</given-names></name>
</person-group><article-title>Aluminium in Cosmetics and Personal Care Products</article-title><source>J. Appl. Toxicol.</source><year>2021</year><volume>41</volume><fpage>1704</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.1002/jat.4228</pub-id><pub-id pub-id-type="pmid">34396567</pub-id></element-citation></ref><ref id="B29-ijms-24-07228"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Scientific Committee on Consumer Safety (SCCS)</collab>
</person-group><source>Preliminary Version of Opinion on the Safety of Aluminium in Cosmetic Products</source><publisher-name>SCCS</publisher-name><publisher-loc>Brussels, Belgium</publisher-loc><year>2022</year></element-citation></ref><ref id="B30-ijms-24-07228"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f6;ffler</surname><given-names>P.</given-names></name>
</person-group><article-title>Review: Vaccine Myth-Buster&#x02014;Cleaning Up With Prejudices and Dangerous Misinformation</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><fpage>2220</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.663280</pub-id></element-citation></ref><ref id="B31-ijms-24-07228"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Principi</surname><given-names>N.</given-names></name>
<name><surname>Esposito</surname><given-names>S.</given-names></name>
</person-group><article-title>Aluminum in Vaccines: Does It Create a Safety Problem?</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5825</fpage><lpage>5831</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.08.036</pub-id><pub-id pub-id-type="pmid">30139653</pub-id></element-citation></ref><ref id="B32-ijms-24-07228"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Qunibi</surname><given-names>W.Y.</given-names></name>
</person-group><source>Aluminum Toxicity in Chronic Kidney Disease</source><person-group person-group-type="editor">
<name><surname>Berns</surname><given-names>J.S.</given-names></name>
<name><surname>Taylor</surname><given-names>E.N.</given-names></name>
</person-group><publisher-name>UpToDate</publisher-name><publisher-loc>Wellesley, MA, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B33-ijms-24-07228"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomljenovic</surname><given-names>L.</given-names></name>
</person-group><article-title>Aluminum and Alzheimer&#x02019;s Disease: After a Century of Controversy, Is There a Plausible Link?</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2011</year><volume>23</volume><fpage>567</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.3233/JAD-2010-101494</pub-id><pub-id pub-id-type="pmid">21157018</pub-id></element-citation></ref><ref id="B34-ijms-24-07228"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akinrinade</surname><given-names>I.D.</given-names></name>
<name><surname>Memudu</surname><given-names>A.E.</given-names></name>
<name><surname>Ogundele</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Fluoride and Aluminium Disturb Neuronal Morphology, Transport Functions, Cholinesterase, Lysosomal and Cell Cycle Activities</article-title><source>Pathophysiology</source><year>2015</year><volume>22</volume><fpage>105</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.pathophys.2015.03.001</pub-id><pub-id pub-id-type="pmid">25863844</pub-id></element-citation></ref><ref id="B35-ijms-24-07228"><label>35.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Caito</surname><given-names>S.</given-names></name>
<name><surname>Aschner</surname><given-names>M.</given-names></name>
</person-group><source>Neurotoxicity of Metals</source><edition>1st ed.</edition><publisher-name>Elsevier, B.V.</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2015</year><volume>Volume 131</volume></element-citation></ref><ref id="B36-ijms-24-07228"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duckett</surname><given-names>S.</given-names></name>
</person-group><article-title>Aluminum and Alzheimer Disease</article-title><source>Arch. Neurol.</source><year>1976</year><volume>33</volume><fpage>730</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1001/archneur.1976.00500100064025</pub-id></element-citation></ref><ref id="B37-ijms-24-07228"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kandimalla</surname><given-names>R.</given-names></name>
<name><surname>Vallamkondu</surname><given-names>J.</given-names></name>
<name><surname>Corgiat</surname><given-names>E.B.</given-names></name>
<name><surname>Gill</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Understanding Aspects of Aluminum Exposure in Alzheimer&#x02019;s Disease Development</article-title><source>Brain Pathol.</source><year>2016</year><volume>26</volume><fpage>139</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1111/bpa.12333</pub-id><pub-id pub-id-type="pmid">26494454</pub-id></element-citation></ref><ref id="B38-ijms-24-07228"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhattacharjee</surname><given-names>S.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Hill</surname><given-names>J.M.</given-names></name>
<name><surname>Culicchia</surname><given-names>F.</given-names></name>
<name><surname>Kruck</surname><given-names>T.P.</given-names></name>
<name><surname>Percy</surname><given-names>M.E.</given-names></name>
<name><surname>Pogue</surname><given-names>A.I.</given-names></name>
<name><surname>Walton</surname><given-names>J.R.</given-names></name>
<name><surname>Lukiw</surname><given-names>W.J.</given-names></name>
</person-group><article-title>Selective accumulation of aluminum in cerebral arteries in Alzheimer&#x02019;s disease (AD)</article-title><source>J. Inorg. Biochem.</source><year>2013</year><volume>126</volume><fpage>35</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2013.05.007</pub-id><pub-id pub-id-type="pmid">23764827</pub-id></element-citation></ref><ref id="B39-ijms-24-07228"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colomina</surname><given-names>M.T.</given-names></name>
<name><surname>Peris-Sampedro</surname><given-names>F.</given-names></name>
</person-group><article-title>Aluminum and Alzheimer&#x02019;s Disease</article-title><source>Adv. Neurobiol.</source><year>2017</year><volume>18</volume><fpage>183</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/978-3-319-60189-2_9</pub-id><pub-id pub-id-type="pmid">28889268</pub-id></element-citation></ref><ref id="B40-ijms-24-07228"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savory</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Herman</surname><given-names>M.M.</given-names></name>
<name><surname>Reyes</surname><given-names>M.R.</given-names></name>
<name><surname>Wills</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Tau Immunoreactivity Associated with Aluminum Maltolate-Induced Neurofibrillary Degeneration in Rabbits</article-title><source>Brain Res.</source><year>1995</year><volume>669</volume><fpage>325</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(94)01297-U</pub-id><pub-id pub-id-type="pmid">7712190</pub-id></element-citation></ref><ref id="B41-ijms-24-07228"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kihira</surname><given-names>T.</given-names></name>
<name><surname>Yoshida</surname><given-names>S.</given-names></name>
<name><surname>Yase</surname><given-names>Y.</given-names></name>
<name><surname>Ono</surname><given-names>S.</given-names></name>
<name><surname>Kondo</surname><given-names>T.</given-names></name>
</person-group><article-title>Chronic Low-Ca/Mg High-Al Diet Induces Neuronal Loss</article-title><source>Neuropathology</source><year>2002</year><volume>22</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1789.2002.00441.x</pub-id><pub-id pub-id-type="pmid">12416556</pub-id></element-citation></ref><ref id="B42-ijms-24-07228"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huat</surname><given-names>T.J.</given-names></name>
<name><surname>Camats-Perna</surname><given-names>J.</given-names></name>
<name><surname>Newcombe</surname><given-names>E.A.</given-names></name>
<name><surname>Valmas</surname><given-names>N.</given-names></name>
<name><surname>Kitazawa</surname><given-names>M.</given-names></name>
<name><surname>Medeiros</surname><given-names>R.</given-names></name>
</person-group><article-title>Metal Toxicity Links to Alzheimer&#x02019;s Disease and Neuroinflammation</article-title><source>J. Mol. Biol.</source><year>2019</year><volume>431</volume><fpage>1843</fpage><lpage>1868</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.01.018</pub-id><pub-id pub-id-type="pmid">30664867</pub-id></element-citation></ref><ref id="B43-ijms-24-07228"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oshima</surname><given-names>E.</given-names></name>
<name><surname>Ishihara</surname><given-names>T.</given-names></name>
<name><surname>Yokota</surname><given-names>O.</given-names></name>
<name><surname>Nakashima-Yasuda</surname><given-names>H.</given-names></name>
<name><surname>Nagao</surname><given-names>S.</given-names></name>
<name><surname>Ikeda</surname><given-names>C.</given-names></name>
<name><surname>Naohara</surname><given-names>J.</given-names></name>
<name><surname>Terada</surname><given-names>S.</given-names></name>
<name><surname>Uchitomi</surname><given-names>Y.</given-names></name>
</person-group><article-title>Accelerated Tau Aggregation, Apoptosis and Neurological Dysfunction Caused by Chronic Oral Administration of Aluminum in a Mouse Model of Tauopathies</article-title><source>Brain Pathol.</source><year>2013</year><volume>23</volume><fpage>633</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1111/bpa.12059</pub-id><pub-id pub-id-type="pmid">23574527</pub-id></element-citation></ref><ref id="B44-ijms-24-07228"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sakamoto</surname><given-names>T.</given-names></name>
<name><surname>Saito</surname><given-names>H.</given-names></name>
<name><surname>Ishii</surname><given-names>K.</given-names></name>
<name><surname>Takahashi</surname><given-names>H.</given-names></name>
<name><surname>Tanabe</surname><given-names>S.</given-names></name>
<name><surname>Ogasawara</surname><given-names>Y.</given-names></name>
</person-group><article-title>Aluminum Inhibits Proteolytic Degradation of Amyloid Beta Peptide by Cathepsin D: A Potential Link between Aluminum Accumulation and Neuritic Plaque Deposition</article-title><source>FEBS Lett.</source><year>2006</year><volume>580</volume><fpage>6543</fpage><lpage>6549</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2006.10.075</pub-id><pub-id pub-id-type="pmid">17112520</pub-id></element-citation></ref><ref id="B45-ijms-24-07228"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ricchelli</surname><given-names>F.</given-names></name>
<name><surname>Drago</surname><given-names>D.</given-names></name>
<name><surname>Filippi</surname><given-names>B.</given-names></name>
<name><surname>Tognon</surname><given-names>G.</given-names></name>
<name><surname>Zatta</surname><given-names>P.</given-names></name>
</person-group><article-title>Aluminum-Triggered Structural Modifications and Aggregation of &#x003b2;-Amyloids</article-title><source>Cell. Mol. Life Sci.</source><year>2005</year><volume>62</volume><fpage>1724</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1007/s00018-005-5141-0</pub-id><pub-id pub-id-type="pmid">15990957</pub-id></element-citation></ref><ref id="B46-ijms-24-07228"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolognin</surname><given-names>S.</given-names></name>
<name><surname>Messori</surname><given-names>L.</given-names></name>
<name><surname>Drago</surname><given-names>D.</given-names></name>
<name><surname>Gabbiani</surname><given-names>C.</given-names></name>
<name><surname>Cendron</surname><given-names>L.</given-names></name>
<name><surname>Zatta</surname><given-names>P.</given-names></name>
</person-group><article-title>Aluminum, Copper, Iron and Zinc Differentially Alter Amyloid-A&#x003b2; 1-42 Aggregation and Toxicity</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2011</year><volume>43</volume><fpage>877</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2011.02.009</pub-id><pub-id pub-id-type="pmid">21376832</pub-id></element-citation></ref><ref id="B47-ijms-24-07228"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Banks</surname><given-names>W.A.</given-names></name>
<name><surname>Niehoff</surname><given-names>M.L.</given-names></name>
<name><surname>Drago</surname><given-names>D.</given-names></name>
<name><surname>Zatta</surname><given-names>P.</given-names></name>
</person-group><article-title>Aluminum Complexing Enhances Amyloid &#x003b2; Protein Penetration of Blood-Brain Barrier</article-title><source>Brain Res.</source><year>2006</year><volume>1116</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.07.112</pub-id><pub-id pub-id-type="pmid">16942756</pub-id></element-citation></ref><ref id="B48-ijms-24-07228"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.B.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.Y.</given-names></name>
<name><surname>Yin</surname><given-names>L.H.</given-names></name>
<name><surname>Schluesener</surname><given-names>H.J.</given-names></name>
</person-group><article-title>The Profile of &#x003b2;-Amyloid Precursor Protein Expression of Rats Induced by Aluminum</article-title><source>Environ. Toxicol. Pharmacol.</source><year>2012</year><volume>33</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.etap.2011.12.005</pub-id><pub-id pub-id-type="pmid">22209725</pub-id></element-citation></ref><ref id="B49-ijms-24-07228"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pratic&#x000f2;</surname><given-names>D.</given-names></name>
<name><surname>Uryu</surname><given-names>K.</given-names></name>
<name><surname>Sung</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>S.</given-names></name>
<name><surname>Trojanowski</surname><given-names>J.Q.</given-names></name>
<name><surname>Lee</surname><given-names>V.M.Y.</given-names></name>
</person-group><article-title>Aluminum Modulates Brain Amyloidosis through Oxidative Stress in APP Transgenic Mice</article-title><source>FASEB J.</source><year>2002</year><volume>16</volume><fpage>1138</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1096/fj.02-0012fje</pub-id><pub-id pub-id-type="pmid">12039845</pub-id></element-citation></ref><ref id="B50-ijms-24-07228"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Platt</surname><given-names>B.</given-names></name>
<name><surname>Drysdale</surname><given-names>A.J.</given-names></name>
<name><surname>Nday</surname><given-names>C.</given-names></name>
<name><surname>Roloff</surname><given-names>E.v.L.</given-names></name>
<name><surname>Drever</surname><given-names>B.D.</given-names></name>
<name><surname>Salifoglou</surname><given-names>A.</given-names></name>
</person-group><article-title>Differential Toxicity of Novel Aluminium Compounds in Hippocampal Culture</article-title><source>Neurotoxicology</source><year>2007</year><volume>28</volume><fpage>576</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1016/j.neuro.2006.12.008</pub-id><pub-id pub-id-type="pmid">17303244</pub-id></element-citation></ref><ref id="B51-ijms-24-07228"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akiyama</surname><given-names>H.</given-names></name>
<name><surname>Hosokawa</surname><given-names>M.</given-names></name>
<name><surname>Kametani</surname><given-names>F.</given-names></name>
<name><surname>Kondo</surname><given-names>H.</given-names></name>
<name><surname>Chiba</surname><given-names>M.</given-names></name>
<name><surname>Fukushima</surname><given-names>M.</given-names></name>
<name><surname>Tabira</surname><given-names>T.</given-names></name>
</person-group><article-title>Long-Term Oral Intake of Aluminium or Zinc Does Not Accelerate Alzheimer Pathology in A&#x003b2;PP and A&#x003b2;PP/Tau Transgenic Mice</article-title><source>Neuropathology</source><year>2012</year><volume>32</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2011.01274.x</pub-id><pub-id pub-id-type="pmid">22118300</pub-id></element-citation></ref><ref id="B52-ijms-24-07228"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribes</surname><given-names>D.</given-names></name>
<name><surname>Colomina</surname><given-names>M.T.</given-names></name>
<name><surname>Vicens</surname><given-names>P.</given-names></name>
<name><surname>Domingo</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Impaired Spatial Learning and Unaltered Neurogenesis in a Transgenic Model of Alzheimer&#x02019;s Disease after Oral Aluminum Exposure</article-title><source>Curr. Alzheimer Res.</source><year>2010</year><volume>7</volume><fpage>401</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.2174/156720510791383840</pub-id><pub-id pub-id-type="pmid">19939225</pub-id></element-citation></ref><ref id="B53-ijms-24-07228"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>J.</given-names></name>
</person-group><article-title>Animal Model of Aluminum-Induced Alzheimer&#x02019;s Disease</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1091</volume><fpage>113</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/978-981-13-1370-7_7</pub-id><pub-id pub-id-type="pmid">30315452</pub-id></element-citation></ref><ref id="B54-ijms-24-07228"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jenkinson</surname><given-names>P.</given-names></name>
</person-group><article-title>Critical Review of the Publications on the Genotoxicology of Aluminium Salts: 1990&#x02013;2018</article-title><source>Mutagenesis</source><year>2021</year><volume>36</volume><fpage>109</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/mutage/geab008</pub-id><pub-id pub-id-type="pmid">33609359</pub-id></element-citation></ref><ref id="B55-ijms-24-07228"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Darbre</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Aluminium and the Human Breast</article-title><source>Morphologie</source><year>2016</year><volume>100</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.morpho.2016.02.001</pub-id><pub-id pub-id-type="pmid">26997127</pub-id></element-citation></ref><ref id="B56-ijms-24-07228"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coulson</surname><given-names>J.M.</given-names></name>
<name><surname>Hughes</surname><given-names>B.W.</given-names></name>
</person-group><article-title>Dose-Response Relationships in Aluminium Toxicity in Humans</article-title><source>Clin. Toxicol.</source><year>2022</year><volume>60</volume><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1080/15563650.2022.2029879</pub-id><pub-id pub-id-type="pmid">35179097</pub-id></element-citation></ref><ref id="B57-ijms-24-07228"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lukiw</surname><given-names>W.J.</given-names></name>
<name><surname>Percy</surname><given-names>M.E.</given-names></name>
<name><surname>Kruck</surname><given-names>T.P.</given-names></name>
</person-group><article-title>Nanomolar Aluminum Induces Pro-Inflammatory and pro-Apoptotic Gene Expression in Human Brain Cells in Primary Culture</article-title><source>J. Inorg. Biochem.</source><year>2005</year><volume>99</volume><fpage>1895</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2005.04.021</pub-id><pub-id pub-id-type="pmid">15961160</pub-id></element-citation></ref><ref id="B58-ijms-24-07228"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klotz</surname><given-names>K.</given-names></name>
<name><surname>Weistenh&#x000f6;fer</surname><given-names>W.</given-names></name>
<name><surname>Neff</surname><given-names>F.</given-names></name>
<name><surname>Hartwig</surname><given-names>A.</given-names></name>
<name><surname>Van Thriel</surname><given-names>C.</given-names></name>
<name><surname>Drexler</surname><given-names>H.</given-names></name>
</person-group><article-title>The Health Effects of Aluminum Exposure</article-title><source>Dtsch. Arztebl. Int.</source><year>2017</year><volume>114</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.3238/arztebl.2017.0653</pub-id><pub-id pub-id-type="pmid">29034866</pub-id></element-citation></ref><ref id="B59-ijms-24-07228"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klein</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Aluminum Toxicity to Bone: A Multisystem Effect?</article-title><source>Osteoporos. Sarcopenia</source><year>2019</year><volume>5</volume><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.afos.2019.01.001</pub-id><pub-id pub-id-type="pmid">31008371</pub-id></element-citation></ref><ref id="B60-ijms-24-07228"><label>60.</label><element-citation publication-type="webpage"><article-title>Dementia</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/news-room/fact-sheets/detail/dementia" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/dementia</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-07">(accessed on 7 December 2022)</date-in-citation></element-citation></ref><ref id="B61-ijms-24-07228"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>D.E.</given-names></name>
<name><surname>Yaffe</surname><given-names>K.</given-names></name>
</person-group><article-title>The Projected Effect of Risk Factor Reduction on Alzheimer&#x02019;s Disease Prevalence</article-title><source>Lancet. Neurol.</source><year>2011</year><volume>10</volume><fpage>819</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(11)70072-2</pub-id><pub-id pub-id-type="pmid">21775213</pub-id></element-citation></ref><ref id="B62-ijms-24-07228"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yumoto</surname><given-names>S.</given-names></name>
<name><surname>Kakimi</surname><given-names>S.</given-names></name>
<name><surname>Ohsaki</surname><given-names>A.</given-names></name>
<name><surname>Ishikawa</surname><given-names>A.</given-names></name>
</person-group><article-title>Demonstration of Aluminum in Amyloid Fibers in the Cores of Senile Plaques in the Brains of Patients with Alzheimer&#x02019;s Disease</article-title><source>J. Inorg. Biochem.</source><year>2009</year><volume>103</volume><fpage>1579</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2009.07.023</pub-id><pub-id pub-id-type="pmid">19744735</pub-id></element-citation></ref><ref id="B63-ijms-24-07228"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rusina</surname><given-names>R.</given-names></name>
<name><surname>Mat&#x0011b;j</surname><given-names>R.</given-names></name>
<name><surname>Ka&#x00161;parov&#x000e1;</surname><given-names>L.</given-names></name>
<name><surname>Kukal</surname><given-names>J.</given-names></name>
<name><surname>Urban</surname><given-names>P.</given-names></name>
</person-group><article-title>Higher Aluminum Concentration in Alzheimer&#x02019;s Disease after Box-Cox Data Transformation</article-title><source>Neurotox. Res.</source><year>2011</year><volume>20</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1007/s12640-011-9246-y</pub-id><pub-id pub-id-type="pmid">21567285</pub-id></element-citation></ref><ref id="B64-ijms-24-07228"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lukiw</surname><given-names>W.J.</given-names></name>
<name><surname>Kruck</surname><given-names>T.P.</given-names></name>
<name><surname>Percy</surname><given-names>M.E.</given-names></name>
<name><surname>Pogue</surname><given-names>A.I.</given-names></name>
<name><surname>Alexandrov</surname><given-names>P.N.</given-names></name>
<name><surname>Walsh</surname><given-names>W.J.</given-names></name>
<name><surname>Sharfman</surname><given-names>N.M.</given-names></name>
<name><surname>Jaber</surname><given-names>V.R.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Aluminum in Neurological Disease&#x02014;A 36 Year Multicenter Study</article-title><source>J. Alzheimer&#x02019;s Dis. Park.</source><year>2018</year><volume>08</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.4172/2161-0460.1000457</pub-id></element-citation></ref><ref id="B65-ijms-24-07228"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akatsu</surname><given-names>H.</given-names></name>
<name><surname>Hori</surname><given-names>A.</given-names></name>
<name><surname>Yamamoto</surname><given-names>T.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
<name><surname>Mimuro</surname><given-names>M.</given-names></name>
<name><surname>Hashizume</surname><given-names>Y.</given-names></name>
<name><surname>Tooyama</surname><given-names>I.</given-names></name>
<name><surname>Yezdimer</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Transition Metal Abnormalities in Progressive Dementias</article-title><source>Biometals</source><year>2012</year><volume>25</volume><fpage>337</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1007/s10534-011-9504-8</pub-id><pub-id pub-id-type="pmid">22080191</pub-id></element-citation></ref><ref id="B66-ijms-24-07228"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virk</surname><given-names>S.A.</given-names></name>
<name><surname>Eslick</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Aluminum Levels in Brain, Serum, and Cerebrospinal Fluid Are Higher in Alzheimer&#x02019;s Disease Cases than in Controls: A Series of Meta-Analyses</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2015</year><volume>47</volume><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.3233/JAD-150193</pub-id><pub-id pub-id-type="pmid">26401698</pub-id></element-citation></ref><ref id="B67-ijms-24-07228"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virk</surname><given-names>S.A.</given-names></name>
<name><surname>Eslick</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Brief Report: Meta-Analysis of Antacid Use and Alzheimer&#x02019;s Disease: Implications for the Aluminum Hypothesis</article-title><source>Epidemiology</source><year>2015</year><volume>26</volume><fpage>769</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1097/EDE.0000000000000326</pub-id><pub-id pub-id-type="pmid">26098935</pub-id></element-citation></ref><ref id="B68-ijms-24-07228"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Suo</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
</person-group><article-title>Chronic Exposure to Aluminum and Risk of Alzheimer&#x02019;s Disease: A Meta-Analysis</article-title><source>Neurosci. Lett.</source><year>2016</year><volume>610</volume><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2015.11.014</pub-id><pub-id pub-id-type="pmid">26592479</pub-id></element-citation></ref><ref id="B69-ijms-24-07228"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virk</surname><given-names>S.A.</given-names></name>
<name><surname>Eslick</surname><given-names>G.D.</given-names></name>
</person-group><article-title>Occupational Exposure to Aluminum and Alzheimer Disease a Meta-Analysis</article-title><source>J. Occup. Environ. Med.</source><year>2015</year><volume>57</volume><fpage>893</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1097/JOM.0000000000000487</pub-id><pub-id pub-id-type="pmid">26247643</pub-id></element-citation></ref><ref id="B70-ijms-24-07228"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rondeau</surname><given-names>V.</given-names></name>
<name><surname>Commenges</surname><given-names>D.</given-names></name>
<name><surname>Jacqmin-Gadda</surname><given-names>H.</given-names></name>
<name><surname>Dartigues</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Relation between Aluminum Concentrations in Drinking Water and Alzheimer&#x02019;s Disease: An 8-Year Follow-up Study</article-title><source>Am. J. Epidemiol.</source><year>2000</year><volume>152</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.1093/aje/152.1.59</pub-id><pub-id pub-id-type="pmid">10901330</pub-id></element-citation></ref><ref id="B71-ijms-24-07228"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rondeau</surname><given-names>V.</given-names></name>
<name><surname>Jacqmin-Gadda</surname><given-names>H.</given-names></name>
<name><surname>Commenges</surname><given-names>D.</given-names></name>
<name><surname>Helmer</surname><given-names>C.</given-names></name>
<name><surname>Dartigues</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Aluminum and Silica in Drinking Water and the Risk of Alzheimer&#x02019;s Disease or Cognitive Decline: Findings from 15-Year Follow-up of the PAQUID Cohort</article-title><source>Am. J. Epidemiol.</source><year>2009</year><volume>169</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1093/aje/kwn348</pub-id><pub-id pub-id-type="pmid">19064650</pub-id></element-citation></ref><ref id="B72-ijms-24-07228"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoke</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Aluminum Chelation: Chemistry, Clinical, and Experimental Studies and the Search for Alternatives to Desferrioxamine</article-title><source>J. Toxicol. Environ. Health</source><year>1994</year><volume>41</volume><fpage>131</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1080/15287399409531834</pub-id><pub-id pub-id-type="pmid">8301696</pub-id></element-citation></ref><ref id="B73-ijms-24-07228"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>M.</given-names></name>
<name><surname>Saraf</surname><given-names>S.</given-names></name>
<name><surname>Saraf</surname><given-names>S.</given-names></name>
<name><surname>Antimisiaris</surname><given-names>S.G.</given-names></name>
<name><surname>Chougule</surname><given-names>M.B.</given-names></name>
<name><surname>Shoyele</surname><given-names>S.A.</given-names></name>
<name><surname>Alexander</surname><given-names>A.</given-names></name>
</person-group><article-title>Nose-to-Brain Drug Delivery: An Update on Clinical Challenges and Progress towards Approval of Anti-Alzheimer Drugs</article-title><source>J. Control. Release</source><year>2018</year><volume>281</volume><fpage>139</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.05.011</pub-id><pub-id pub-id-type="pmid">29772289</pub-id></element-citation></ref><ref id="B74-ijms-24-07228"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davenward</surname><given-names>S.</given-names></name>
<name><surname>Bentham</surname><given-names>P.</given-names></name>
<name><surname>Wright</surname><given-names>J.</given-names></name>
<name><surname>Crome</surname><given-names>P.</given-names></name>
<name><surname>Job</surname><given-names>D.</given-names></name>
<name><surname>Polwart</surname><given-names>A.</given-names></name>
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Silicon-Rich Mineral Water as a Non-Invasive Test of the &#x0201c;Aluminum Hypothesis&#x0201d; in Alzheimer&#x02019;s Disease</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2013</year><volume>33</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.3233/JAD-2012-121231</pub-id><pub-id pub-id-type="pmid">22976072</pub-id></element-citation></ref><ref id="B75-ijms-24-07228"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exley</surname><given-names>C.</given-names></name>
<name><surname>Korchazhkina</surname><given-names>O.</given-names></name>
<name><surname>Job</surname><given-names>D.</given-names></name>
<name><surname>Strekopytov</surname><given-names>S.</given-names></name>
<name><surname>Polwart</surname><given-names>A.</given-names></name>
<name><surname>Crome</surname><given-names>P.</given-names></name>
</person-group><article-title>Non-Invasive Therapy to Reduce the Body Burden of Aluminium in Alzheimer&#x02019;s Disease</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2006</year><volume>10</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.3233/JAD-2006-10103</pub-id><pub-id pub-id-type="pmid">16988476</pub-id></element-citation></ref><ref id="B76-ijms-24-07228"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mold</surname><given-names>M.</given-names></name>
<name><surname>Umar</surname><given-names>D.</given-names></name>
<name><surname>King</surname><given-names>A.</given-names></name>
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Aluminium in Brain Tissue in Autism</article-title><source>J. Trace Elem. Med. Biol.</source><year>2018</year><volume>46</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jtemb.2017.11.012</pub-id><pub-id pub-id-type="pmid">29413113</pub-id></element-citation></ref><ref id="B77-ijms-24-07228"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grochowski</surname><given-names>C.</given-names></name>
<name><surname>Blicharska</surname><given-names>E.</given-names></name>
<name><surname>Bogucki</surname><given-names>J.</given-names></name>
<name><surname>Proch</surname><given-names>J.</given-names></name>
<name><surname>Mierzwi&#x00144;ska</surname><given-names>A.</given-names></name>
<name><surname>Baj</surname><given-names>J.</given-names></name>
<name><surname>Litak</surname><given-names>J.</given-names></name>
<name><surname>Podkowi&#x00144;ski</surname><given-names>A.</given-names></name>
<name><surname>Flieger</surname><given-names>J.</given-names></name>
<name><surname>Teresi&#x00144;ski</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Increased Aluminum Content in Certain Brain Structures Is Correlated with Higher Silicon Concentration in Alcoholic Use Disorder</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>1721</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24091721</pub-id><pub-id pub-id-type="pmid">31058813</pub-id></element-citation></ref><ref id="B78-ijms-24-07228"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exley</surname><given-names>C.</given-names></name>
<name><surname>Clarkson</surname><given-names>E.</given-names></name>
</person-group><article-title>Aluminium in Human Brain Tissue from Donors without Neurodegenerative Disease: A Comparison with Alzheimer&#x02019;s Disease, Multiple Sclerosis and Autism</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>7770</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-64734-6</pub-id><pub-id pub-id-type="pmid">32385326</pub-id></element-citation></ref><ref id="B79-ijms-24-07228"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamburo</surname><given-names>E.</given-names></name>
<name><surname>Varrica</surname><given-names>D.</given-names></name>
<name><surname>Dongarr&#x000e0;</surname><given-names>G.</given-names></name>
<name><surname>Grimaldi</surname><given-names>L.M.E.</given-names></name>
</person-group><article-title>Trace Elements in Scalp Hair Samples from Patients with Relapsing-Remitting Multiple Sclerosis</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0122142</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0122142</pub-id><pub-id pub-id-type="pmid">25856388</pub-id></element-citation></ref><ref id="B80-ijms-24-07228"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Exley</surname><given-names>C.</given-names></name>
<name><surname>Mamutse</surname><given-names>G.</given-names></name>
<name><surname>Korchazhkina</surname><given-names>O.</given-names></name>
<name><surname>Pye</surname><given-names>E.</given-names></name>
<name><surname>Strekopytov</surname><given-names>S.</given-names></name>
<name><surname>Polwart</surname><given-names>A.</given-names></name>
<name><surname>Hawkins</surname><given-names>C.</given-names></name>
</person-group><article-title>Elevated Urinary Excretion of Aluminium and Iron in Multiple Sclerosis</article-title><source>Mult. Scler.</source><year>2006</year><volume>12</volume><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1177/1352458506071323</pub-id><pub-id pub-id-type="pmid">17086897</pub-id></element-citation></ref><ref id="B81-ijms-24-07228"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mcdermott</surname><given-names>J.R.</given-names></name>
<name><surname>Smith</surname><given-names>A.I.</given-names></name>
<name><surname>Ward</surname><given-names>M.K.</given-names></name>
<name><surname>Parkinson</surname><given-names>I.S.</given-names></name>
<name><surname>Kerr</surname><given-names>D.N.S.</given-names></name>
</person-group><article-title>Brain-Aluminium Concentration in Dialysis Encephalopathy</article-title><source>Lancet (Lond. Engl.)</source><year>1978</year><volume>1</volume><fpage>901</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(78)90681-5</pub-id></element-citation></ref><ref id="B82-ijms-24-07228"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alfrey</surname><given-names>A.C.</given-names></name>
<name><surname>LeGendre</surname><given-names>G.R.</given-names></name>
<name><surname>Kaehny</surname><given-names>W.D.</given-names></name>
</person-group><article-title>The Dialysis Encephalopathy Syndrome. Possible Aluminum Intoxication</article-title><source>N. Engl. J. Med.</source><year>1976</year><volume>294</volume><fpage>184</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1056/NEJM197601222940402</pub-id><pub-id pub-id-type="pmid">1244532</pub-id></element-citation></ref><ref id="B83-ijms-24-07228"><label>83.</label><element-citation publication-type="webpage"><article-title>Autism Spectrum Disorder in children and adolescents: Terminology, Epidemiology, and Pathogenesis&#x02014;UpToDate</article-title><comment>Available online: <ext-link xlink:href="https://www.uptodate.com/contents/autism-spectrum-disorder-terminology-epidemiology-and-pathogenesis?search=aluminum&#x00026;and&#x00026;autism&#x00026;spectrum&#x00026;disorder&#x00026;source=search_result&#x00026;selectedTitle=6~150&#x00026;usage_type=default&#x00026;display_rank=6" ext-link-type="uri">https://www.uptodate.com/contents/autism-spectrum-disorder-terminology-epidemiology-and-pathogenesis?search=aluminum&#x00026;and&#x00026;autism&#x00026;spectrum&#x00026;disorder&#x00026;source=search_result&#x00026;selectedTitle=6~150&#x00026;usage_type=default&#x00026;display_rank=6</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-10">(accessed on 10 December 2022)</date-in-citation></element-citation></ref><ref id="B84-ijms-24-07228"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nevison</surname><given-names>C.D.</given-names></name>
</person-group><article-title>A Comparison of Temporal Trends in United States Autism Prevalence to Trends in Suspected Environmental Factors</article-title><source>Environ. Health</source><year>2014</year><volume>13</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/1476-069X-13-73</pub-id><pub-id pub-id-type="pmid">25189402</pub-id></element-citation></ref><ref id="B85-ijms-24-07228"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sulaiman</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Ren</surname><given-names>X.</given-names></name>
</person-group><article-title>Exposure to Aluminum, Cadmium, and Mercury and Autism Spectrum Disorder in Children: A Systematic Review and Meta-Analysis</article-title><source>Chem. Res. Toxicol.</source><year>2020</year><volume>33</volume><fpage>2699</fpage><lpage>2718</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00167</pub-id><pub-id pub-id-type="pmid">32990432</pub-id></element-citation></ref><ref id="B86-ijms-24-07228"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amadi</surname><given-names>C.N.</given-names></name>
<name><surname>Orish</surname><given-names>C.N.</given-names></name>
<name><surname>Frazzoli</surname><given-names>C.</given-names></name>
<name><surname>Orisakwe</surname><given-names>O.E.</given-names></name>
</person-group><article-title>Association of Autism with Toxic Metals: A Systematic Review of Case-Control Studies</article-title><source>Pharmacol. Biochem. Behav.</source><year>2022</year><volume>212</volume><elocation-id>173313</elocation-id><pub-id pub-id-type="doi">10.1016/j.pbb.2021.173313</pub-id><pub-id pub-id-type="pmid">34896416</pub-id></element-citation></ref><ref id="B87-ijms-24-07228"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bjorklund</surname><given-names>G.</given-names></name>
<name><surname>Stejskal</surname><given-names>V.</given-names></name>
<name><surname>Urbina</surname><given-names>M.A.</given-names></name>
<name><surname>Dadar</surname><given-names>M.</given-names></name>
<name><surname>Chirumbolo</surname><given-names>S.</given-names></name>
<name><surname>Mutter</surname><given-names>J.</given-names></name>
</person-group><article-title>Metals and Parkinson&#x02019;s Disease: Mechanisms and Biochemical Processes</article-title><source>Curr. Med. Chem.</source><year>2018</year><volume>25</volume><fpage>2198</fpage><lpage>2214</lpage><pub-id pub-id-type="doi">10.2174/0929867325666171129124616</pub-id><pub-id pub-id-type="pmid">29189118</pub-id></element-citation></ref><ref id="B88-ijms-24-07228"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomljenovic</surname><given-names>L.</given-names></name>
<name><surname>Shaw</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Do Aluminum Vaccine Adjuvants Contribute to the Rising Prevalence of Autism?</article-title><source>J. Inorg. Biochem.</source><year>2011</year><volume>105</volume><fpage>1489</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2011.08.008</pub-id><pub-id pub-id-type="pmid">22099159</pub-id></element-citation></ref><ref id="B89-ijms-24-07228"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baj</surname><given-names>J.</given-names></name>
<name><surname>Flieger</surname><given-names>W.</given-names></name>
<name><surname>Flieger</surname><given-names>M.</given-names></name>
<name><surname>Forma</surname><given-names>A.</given-names></name>
<name><surname>Sitarz</surname><given-names>E.</given-names></name>
<name><surname>Sk&#x000f3;rzy&#x00144;ska-Dziduszko</surname><given-names>K.</given-names></name>
<name><surname>Grochowski</surname><given-names>C.</given-names></name>
<name><surname>Maciejewski</surname><given-names>R.</given-names></name>
<name><surname>Karaku&#x00142;a-Juchnowicz</surname><given-names>H.</given-names></name>
</person-group><article-title>Autism Spectrum Disorder: Trace Elements Imbalances and the Pathogenesis and Severity of Autistic Symptoms</article-title><source>Neurosci. Biobehav. Rev.</source><year>2021</year><volume>129</volume><fpage>117</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.07.029</pub-id><pub-id pub-id-type="pmid">34339708</pub-id></element-citation></ref><ref id="B90-ijms-24-07228"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grandjean</surname><given-names>P.</given-names></name>
<name><surname>Landrigan</surname><given-names>P.</given-names></name>
</person-group><article-title>Developmental Neurotoxicity of Industrial Chemicals</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>2167</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69665-7</pub-id><pub-id pub-id-type="pmid">17174709</pub-id></element-citation></ref><ref id="B91-ijms-24-07228"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Landrigan</surname><given-names>P.J.</given-names></name>
</person-group><article-title>What Causes Autism? Exploring the Environmental Contribution</article-title><source>Curr. Opin. Pediatr.</source><year>2010</year><volume>22</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1097/MOP.0b013e328336eb9a</pub-id><pub-id pub-id-type="pmid">20087185</pub-id></element-citation></ref><ref id="B92-ijms-24-07228"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corkins</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Aluminum Effects in Infants and Children</article-title><source>Pediatrics</source><year>2019</year><volume>144</volume><fpage>e20193148</fpage><pub-id pub-id-type="doi">10.1542/peds.2019-3148</pub-id><pub-id pub-id-type="pmid">31767714</pub-id></element-citation></ref><ref id="B93-ijms-24-07228"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrovsky</surname><given-names>N.</given-names></name>
</person-group><article-title>Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs</article-title><source>Drug Saf.</source><year>2015</year><volume>38</volume><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1007/s40264-015-0350-4</pub-id><pub-id pub-id-type="pmid">26446142</pub-id></element-citation></ref><ref id="B94-ijms-24-07228"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitkus</surname><given-names>R.J.</given-names></name>
<name><surname>King</surname><given-names>D.B.</given-names></name>
<name><surname>Hess</surname><given-names>M.A.</given-names></name>
<name><surname>Forshee</surname><given-names>R.A.</given-names></name>
<name><surname>Walderhaug</surname><given-names>M.O.</given-names></name>
</person-group><article-title>Updated Aluminum Pharmacokinetics Following Infant Exposures through Diet and Vaccination</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>9538</fpage><lpage>9543</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.124</pub-id><pub-id pub-id-type="pmid">22001122</pub-id></element-citation></ref><ref id="B95-ijms-24-07228"><label>95.</label><element-citation publication-type="gov"><article-title>Minimal Risk Levels for Hazardous Substances|ATSDR</article-title><comment>Available online: <ext-link xlink:href="https://wwwn.cdc.gov/TSP/MRLS/mrlslisting.aspx" ext-link-type="uri">https://wwwn.cdc.gov/TSP/MRLS/mrlslisting.aspx</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-12-12">(accessed on 12 December 2022)</date-in-citation></element-citation></ref><ref id="B96-ijms-24-07228"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karwowski</surname><given-names>M.P.</given-names></name>
<name><surname>Stamoulis</surname><given-names>C.</given-names></name>
<name><surname>Wenren</surname><given-names>L.M.</given-names></name>
<name><surname>Faboyede</surname><given-names>G.M.</given-names></name>
<name><surname>Quinn</surname><given-names>N.</given-names></name>
<name><surname>Gura</surname><given-names>K.M.</given-names></name>
<name><surname>Bellinger</surname><given-names>D.C.</given-names></name>
<name><surname>Woolf</surname><given-names>A.D.</given-names></name>
</person-group><article-title>Blood and Hair Aluminum Levels, Vaccine History, and Early Infant Development: A Cross-Sectional Study</article-title><source>Acad. Pediatr.</source><year>2018</year><volume>18</volume><fpage>161</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.acap.2017.09.003</pub-id><pub-id pub-id-type="pmid">28919482</pub-id></element-citation></ref><ref id="B97-ijms-24-07228"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>I.</given-names></name>
<name><surname>Behl</surname><given-names>T.</given-names></name>
<name><surname>Aleya</surname><given-names>L.</given-names></name>
<name><surname>Rahman</surname><given-names>M.H.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Arora</surname><given-names>S.</given-names></name>
<name><surname>Akter</surname><given-names>R.</given-names></name>
</person-group><article-title>Role of Metallic Pollutants in Neurodegeneration: Effects of Aluminum, Lead, Mercury, and Arsenic in Mediating Brain Impairment Events and Autism Spectrum Disorder</article-title><source>Environ. Sci. Pollut. Res. Int.</source><year>2021</year><volume>28</volume><fpage>8989</fpage><lpage>9001</lpage><pub-id pub-id-type="doi">10.1007/s11356-020-12255-0</pub-id><pub-id pub-id-type="pmid">33447979</pub-id></element-citation></ref><ref id="B98-ijms-24-07228"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>A.F.</given-names></name>
<name><surname>Heilig</surname><given-names>M.</given-names></name>
<name><surname>Perez</surname><given-names>A.</given-names></name>
<name><surname>Probst</surname><given-names>C.</given-names></name>
<name><surname>Rehm</surname><given-names>J.</given-names></name>
</person-group><article-title>Alcohol Use Disorders</article-title><source>Lancet</source><year>2019</year><volume>394</volume><fpage>781</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31775-1</pub-id><pub-id pub-id-type="pmid">31478502</pub-id></element-citation></ref><ref id="B99-ijms-24-07228"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Davis</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Is Aluminium an Etiologic Contributor to Alcoholic Amnesia and Dementia?</article-title><source>Med. Hypotheses</source><year>1993</year><volume>41</volume><fpage>341</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/0306-9877(93)90079-6</pub-id><pub-id pub-id-type="pmid">8289699</pub-id></element-citation></ref><ref id="B100-ijms-24-07228"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharpe</surname><given-names>F.R.</given-names></name>
<name><surname>Vobe</surname><given-names>R.A.</given-names></name>
<name><surname>Williams</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Chemical Speciation of Aluminium in Beers</article-title><source>Chem. Speciat. Bioavailab.</source><year>1995</year><volume>7</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1080/09542299.1995.11083242</pub-id></element-citation></ref><ref id="B101-ijms-24-07228"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blanco</surname><given-names>C.A.</given-names></name>
<name><surname>Sancho</surname><given-names>D.</given-names></name>
<name><surname>Caballero</surname><given-names>I.</given-names></name>
</person-group><article-title>Aluminium Content in Beers and Silicon Sequestering Effects</article-title><source>Food Res. Int.</source><year>2010</year><volume>43</volume><fpage>2432</fpage><lpage>2436</lpage><pub-id pub-id-type="doi">10.1016/j.foodres.2010.09.017</pub-id></element-citation></ref><ref id="B102-ijms-24-07228"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Granero</surname><given-names>S.</given-names></name>
<name><surname>Vicente</surname><given-names>M.</given-names></name>
<name><surname>Aguilar</surname><given-names>V.</given-names></name>
<name><surname>Martinez-Para</surname><given-names>M.C.</given-names></name>
<name><surname>Domingo</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Effects of Beer as a Source of Dietary Silicon on Aluminum Absorption and Retention in Mice</article-title><source>Trace Elem. Electrolytes</source><year>2004</year><volume>21</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.5414/TEP21028</pub-id></element-citation></ref><ref id="B103-ijms-24-07228"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schultz</surname><given-names>A.</given-names></name>
<name><surname>Oliver</surname><given-names>R.</given-names></name>
<name><surname>Bautista</surname><given-names>M.</given-names></name>
<name><surname>Gonzalez-Mu&#x000f1;oz</surname><given-names>M.J.</given-names></name>
<name><surname>Meseguer</surname><given-names>I.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>A.</given-names></name>
<name><surname>Sanchez-Reus</surname><given-names>M.I.</given-names></name>
<name><surname>Bened&#x000ed;</surname><given-names>J.</given-names></name>
<name><surname>S&#x000e1;nchez-Muniz</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Moderate Ingestion of Beer Reduces Inflammatory and Oxidative Brain Events Induced by Aluminium in Mice</article-title><source>Proc. Nutr. Soc.</source><year>2008</year><volume>67</volume><fpage>E69</fpage><pub-id pub-id-type="doi">10.1017/S0029665108006782</pub-id></element-citation></ref><ref id="B104-ijms-24-07228"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Mu&#x000f1;oz</surname><given-names>M.J.</given-names></name>
<name><surname>Pe&#x000f1;a</surname><given-names>A.</given-names></name>
<name><surname>Meseguer</surname><given-names>I.</given-names></name>
</person-group><article-title>Role of Beer as a Possible Protective Factor in Preventing Alzheimer&#x02019;s Disease</article-title><source>Food Chem. Toxicol.</source><year>2008</year><volume>46</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2007.06.036</pub-id><pub-id pub-id-type="pmid">17697731</pub-id></element-citation></ref><ref id="B105-ijms-24-07228"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e1;nchez-Muniz</surname><given-names>F.J.</given-names></name>
<name><surname>Macho-Gonz&#x000e1;lez</surname><given-names>A.</given-names></name>
<name><surname>Garcimartin</surname><given-names>A.</given-names></name>
<name><surname>Santos-L&#x000f3;pez</surname><given-names>J.A.</given-names></name>
<name><surname>Benedi</surname><given-names>J.</given-names></name>
<name><surname>Bastida</surname><given-names>S.</given-names></name>
<name><surname>Gonzsez-Munoz</surname><given-names>M.J.</given-names></name>
</person-group><article-title>The Nutritional Components of Beer and Its Relationship with Neurodegeneration and Alzheimer&#x02019;s Disease</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>1558</elocation-id><pub-id pub-id-type="doi">10.3390/nu11071558</pub-id><pub-id pub-id-type="pmid">31295866</pub-id></element-citation></ref><ref id="B106-ijms-24-07228"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonz&#x000e1;lez-Mu&#x000f1;oz</surname><given-names>M.J.</given-names></name>
<name><surname>Garcimart&#x000e1;n</surname><given-names>A.</given-names></name>
<name><surname>Meseguer</surname><given-names>I.</given-names></name>
<name><surname>Mateos-Vega</surname><given-names>C.J.</given-names></name>
<name><surname>Orellana</surname><given-names>J.M.</given-names></name>
<name><surname>Pe&#x000f1;a-Fern&#x000e1;ndez</surname><given-names>A.</given-names></name>
<name><surname>Bened&#x000ed;</surname><given-names>J.</given-names></name>
<name><surname>S&#x000e1;nchez-Muniz</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Silicic Acid and Beer Consumption Reverses the Metal Imbalance and the Prooxidant Status Induced by Aluminum Nitrate in Mouse Brain</article-title><source>J. Alzheimer&#x02019;s Dis.</source><year>2017</year><volume>56</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.3233/JAD-160972</pub-id><pub-id pub-id-type="pmid">28059788</pub-id></element-citation></ref><ref id="B107-ijms-24-07228"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gonzalez-Mu&#x000f1;oz</surname><given-names>M.J.</given-names></name>
<name><surname>Meseguer</surname><given-names>I.</given-names></name>
<name><surname>Sanchez-Reus</surname><given-names>M.I.</given-names></name>
<name><surname>Schultz</surname><given-names>A.</given-names></name>
<name><surname>Olivero</surname><given-names>R.</given-names></name>
<name><surname>Bened&#x000ed;</surname><given-names>J.</given-names></name>
<name><surname>S&#x000e1;nchez-Muniz</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Beer Consumption Reduces Cerebral Oxidation Caused by Aluminum Toxicity by Normalizing Gene Expression of Tumor Necrotic Factor Alpha and Several Antioxidant Enzymes</article-title><source>Food Chem. Toxicol.</source><year>2008</year><volume>46</volume><fpage>1111</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2007.11.006</pub-id><pub-id pub-id-type="pmid">18096288</pub-id></element-citation></ref><ref id="B108-ijms-24-07228"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>D.R.</given-names></name>
<name><surname>Wani</surname><given-names>W.Y.</given-names></name>
<name><surname>Sunkaria</surname><given-names>A.</given-names></name>
<name><surname>Kandimalla</surname><given-names>R.J.</given-names></name>
<name><surname>Sharma</surname><given-names>R.K.</given-names></name>
<name><surname>Verma</surname><given-names>D.</given-names></name>
<name><surname>Bal</surname><given-names>A.</given-names></name>
<name><surname>Gill</surname><given-names>K.D.</given-names></name>
</person-group><article-title>Quercetin Attenuates Neuronal Death against Aluminum-Induced Neurodegeneration in the Rat Hippocampus</article-title><source>Neuroscience</source><year>2016</year><volume>324</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.02.055</pub-id><pub-id pub-id-type="pmid">26944603</pub-id></element-citation></ref><ref id="B109-ijms-24-07228"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laabbar</surname><given-names>W.</given-names></name>
<name><surname>Elgot</surname><given-names>A.</given-names></name>
<name><surname>Elhiba</surname><given-names>O.</given-names></name>
<name><surname>Gamrani</surname><given-names>H.</given-names></name>
</person-group><article-title>Curcumin Prevents the Midbrain Dopaminergic Innervations and Locomotor Performance Deficiencies Resulting from Chronic Aluminum Exposure in Rat</article-title><source>J. Chem. Neuroanat.</source><year>2019</year><volume>100</volume><fpage>101654</fpage><pub-id pub-id-type="doi">10.1016/j.jchemneu.2019.101654</pub-id><pub-id pub-id-type="pmid">31170442</pub-id></element-citation></ref><ref id="B110-ijms-24-07228"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Firdaus</surname><given-names>Z.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
<name><surname>Singh</surname><given-names>S.K.</given-names></name>
<name><surname>Singh</surname><given-names>T.D.</given-names></name>
</person-group><article-title>Centella Asiatica Alleviates AlCl3-Induced Cognitive Impairment, Oxidative Stress, and Neurodegeneration by Modulating Cholinergic Activity and Oxidative Burden in Rat Brain</article-title><source>Biol. Trace Elem. Res.</source><year>2022</year><volume>200</volume><fpage>5115</fpage><lpage>5126</lpage><pub-id pub-id-type="doi">10.1007/s12011-021-03083-5</pub-id><pub-id pub-id-type="pmid">34984596</pub-id></element-citation></ref><ref id="B111-ijms-24-07228"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dobson</surname><given-names>R.</given-names></name>
<name><surname>Giovannoni</surname><given-names>G.</given-names></name>
</person-group><article-title>Multiple Sclerosis&#x02014;A Review</article-title><source>Eur. J. Neurol.</source><year>2019</year><volume>26</volume><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1111/ene.13819</pub-id><pub-id pub-id-type="pmid">30300457</pub-id></element-citation></ref><ref id="B112-ijms-24-07228"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mold</surname><given-names>M.</given-names></name>
<name><surname>Chmielecka</surname><given-names>A.</given-names></name>
<name><surname>Rodriguez</surname><given-names>M.R.R.</given-names></name>
<name><surname>Thom</surname><given-names>F.</given-names></name>
<name><surname>Linhart</surname><given-names>C.</given-names></name>
<name><surname>King</surname><given-names>A.</given-names></name>
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Aluminium in Brain Tissue in Multiple Sclerosis</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>15</volume><elocation-id>1777</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph15081777</pub-id><pub-id pub-id-type="pmid">30126209</pub-id></element-citation></ref><ref id="B113-ijms-24-07228"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linhart</surname><given-names>C.</given-names></name>
<name><surname>Davidson</surname><given-names>D.</given-names></name>
<name><surname>Pathmanathan</surname><given-names>S.</given-names></name>
<name><surname>Kamaladas</surname><given-names>T.</given-names></name>
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Aluminium in Brain Tissue in Non-Neurodegenerative/Non-Neurodevelopmental Disease: A Comparison with Multiple Sclerosis</article-title><source>Expo. Health</source><year>2020</year><volume>12</volume><fpage>863</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1007/s12403-020-00346-9</pub-id></element-citation></ref><ref id="B114-ijms-24-07228"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>K.</given-names></name>
<name><surname>Linhart</surname><given-names>C.</given-names></name>
<name><surname>Hawkins</surname><given-names>C.</given-names></name>
<name><surname>Exley</surname><given-names>C.</given-names></name>
</person-group><article-title>Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis</article-title><source>EBioMedicine</source><year>2017</year><volume>26</volume><fpage>60</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2017.10.028</pub-id><pub-id pub-id-type="pmid">29128442</pub-id></element-citation></ref><ref id="B115-ijms-24-07228"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fulgenzi</surname><given-names>A.</given-names></name>
<name><surname>Vietti</surname><given-names>D.</given-names></name>
<name><surname>Ferrero</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Aluminium Involvement in Neurotoxicity</article-title><source>Biomed Res. Int.</source><year>2014</year><volume>2014</volume><elocation-id>758323</elocation-id><pub-id pub-id-type="doi">10.1155/2014/758323</pub-id><pub-id pub-id-type="pmid">25243176</pub-id></element-citation></ref><ref id="B116-ijms-24-07228"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fulgenzi</surname><given-names>A.</given-names></name>
<name><surname>Zanella</surname><given-names>S.G.</given-names></name>
<name><surname>Mariani</surname><given-names>M.M.</given-names></name>
<name><surname>Vietti</surname><given-names>D.</given-names></name>
<name><surname>Ferrero</surname><given-names>M.E.</given-names></name>
</person-group><article-title>A Case of Multiple Sclerosis Improvement Following Removal of Heavy Metal Intoxication</article-title><source>BioMetals</source><year>2012</year><volume>25</volume><fpage>569</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1007/s10534-012-9537-7</pub-id><pub-id pub-id-type="pmid">22438029</pub-id></element-citation></ref><ref id="B117-ijms-24-07228"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radhakrishnan</surname><given-names>D.M.</given-names></name>
<name><surname>Goyal</surname><given-names>V.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s Disease: A Review</article-title><source>Neurol. India</source><year>2018</year><volume>66</volume><fpage>S26</fpage><lpage>S35</lpage><pub-id pub-id-type="doi">10.4103/0028-3886.226451</pub-id><pub-id pub-id-type="pmid">29503325</pub-id></element-citation></ref><ref id="B118-ijms-24-07228"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beitz</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s Disease: A Review</article-title><source>Front. Biosci. (Sch. Ed.)</source><year>2014</year><volume>6</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.2741/S415</pub-id></element-citation></ref><ref id="B119-ijms-24-07228"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>E.C.</given-names></name>
<name><surname>Brandel</surname><given-names>J.-P.</given-names></name>
<name><surname>Galle</surname><given-names>P.</given-names></name>
<name><surname>Javoy-Agid</surname><given-names>F.</given-names></name>
<name><surname>Agid</surname><given-names>Y.</given-names></name>
</person-group><article-title>Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson&#x02019;s Disease: An X-ray Microanalysis</article-title><source>J. Neurochem.</source><year>1991</year><volume>56</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb08170.x</pub-id><pub-id pub-id-type="pmid">1988548</pub-id></element-citation></ref><ref id="B120-ijms-24-07228"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erazi</surname><given-names>H.</given-names></name>
<name><surname>Ahboucha</surname><given-names>S.</given-names></name>
<name><surname>Gamrani</surname><given-names>H.</given-names></name>
</person-group><article-title>Chronic Exposure to Aluminum Reduces Tyrosine Hydroxylase Expression in the Substantia Nigra and Locomotor Performance in Rats</article-title><source>Neurosci. Lett.</source><year>2011</year><volume>487</volume><fpage>8</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2010.09.053</pub-id><pub-id pub-id-type="pmid">20884324</pub-id></element-citation></ref><ref id="B121-ijms-24-07228"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>X.</given-names></name>
<name><surname>Macleod</surname><given-names>J.</given-names></name>
<name><surname>Berriault</surname><given-names>C.</given-names></name>
<name><surname>Debono</surname><given-names>N.L.</given-names></name>
<name><surname>Arrandale</surname><given-names>V.H.</given-names></name>
<name><surname>Harris</surname><given-names>A.M.</given-names></name>
<name><surname>Demers</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Aluminum Dust Exposure and Risk of Neurodegenerative Diseases in a Cohort of Male Miners in Ontario, Canada</article-title><source>Scand. J. Work. Environ. Health</source><year>2021</year><volume>47</volume><fpage>531</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.5271/sjweh.3974</pub-id><pub-id pub-id-type="pmid">34591975</pub-id></element-citation></ref><ref id="B122-ijms-24-07228"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martell</surname><given-names>J.</given-names></name>
<name><surname>Guidotti</surname><given-names>T.L.</given-names></name>
</person-group><article-title>Trading One Risk for Another: Consequences of the Unauthenticated Treatment and Prevention of Silicosis in Ontario Miners in the McIntyre Powder Aluminum Inhalation Program</article-title><source>New Solut.</source><year>2022</year><volume>31</volume><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1177/10482911211037007</pub-id><pub-id pub-id-type="pmid">34365861</pub-id></element-citation></ref><ref id="B123-ijms-24-07228"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gorell</surname><given-names>J.M.</given-names></name>
<name><surname>Rybicki</surname><given-names>B.A.</given-names></name>
<name><surname>Johnson</surname><given-names>C.C.</given-names></name>
<name><surname>Peterson</surname><given-names>E.L.</given-names></name>
</person-group><article-title>Occupational Metal Exposures and the Risk of Parkinson&#x02019;s Disease</article-title><source>Neuroepidemiology</source><year>1999</year><volume>18</volume><fpage>303</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1159/000026225</pub-id><pub-id pub-id-type="pmid">10545782</pub-id></element-citation></ref><ref id="B124-ijms-24-07228"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uversky</surname><given-names>V.N.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Bower</surname><given-names>K.</given-names></name>
<name><surname>Fink</surname><given-names>A.L.</given-names></name>
</person-group><article-title>Synergistic Effects of Pesticides and Metals on the Fibrillation of Alpha-Synuclein: Implications for Parkinson&#x02019;s Disease</article-title><source>Neurotoxicology</source><year>2002</year><volume>23</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/S0161-813X(02)00067-0</pub-id><pub-id pub-id-type="pmid">12428725</pub-id></element-citation></ref><ref id="B125-ijms-24-07228"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Altschuler</surname><given-names>E.</given-names></name>
</person-group><article-title>Aluminum-Containing Antacids as a Cause of Idiopathic Parkinson&#x02019;s Disease</article-title><source>Med. Hypotheses</source><year>1999</year><volume>53</volume><fpage>22</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1054/mehy.1997.0701</pub-id><pub-id pub-id-type="pmid">10499820</pub-id></element-citation></ref><ref id="B126-ijms-24-07228"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>S.S.S.J.</given-names></name>
<name><surname>Santosh</surname><given-names>W.</given-names></name>
</person-group><article-title>Metallomic Profiling and Linkage Map Analysis of Early Parkinson&#x02019;s Disease: A New Insight to Aluminum Marker for the Possible Diagnosis</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e11252</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0011252</pub-id><pub-id pub-id-type="pmid">20582167</pub-id></element-citation></ref><ref id="B127-ijms-24-07228"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>Advances in Dialysis Encephalopathy Research: A Review</article-title><source>Neurol. Sci.</source><year>2018</year><volume>39</volume><fpage>1151</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1007/s10072-018-3426-y</pub-id><pub-id pub-id-type="pmid">29721635</pub-id></element-citation></ref><ref id="B128-ijms-24-07228"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dryburgh</surname><given-names>F.</given-names></name>
<name><surname>Fell</surname><given-names>G.S.</given-names></name>
<name><surname>Sabet</surname><given-names>S.</given-names></name>
</person-group><article-title>Aluminium Toxicity during Regular Haemodialysis</article-title><source>Br. Med. J.</source><year>1978</year><volume>1</volume><fpage>1101</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1136/BMJ.1.6120.1101</pub-id><pub-id pub-id-type="pmid">638617</pub-id></element-citation></ref><ref id="B129-ijms-24-07228"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ritz</surname><given-names>E.</given-names></name>
<name><surname>Hergesell</surname><given-names>O.</given-names></name>
</person-group><article-title>Compounds in Development to Combat Hyperphosphataemia</article-title><source>Expert Opin. Investig. Drugs</source><year>2001</year><volume>10</volume><fpage>2185</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.1517/13543784.10.12.2185</pub-id><pub-id pub-id-type="pmid">11772314</pub-id></element-citation></ref><ref id="B130-ijms-24-07228"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Canavese</surname><given-names>C.</given-names></name>
<name><surname>Mereu</surname><given-names>C.</given-names></name>
<name><surname>Nordio</surname><given-names>M.</given-names></name>
<name><surname>Sabbioni</surname><given-names>E.</given-names></name>
<name><surname>Aime</surname><given-names>S.</given-names></name>
</person-group><article-title>Blast from the Past: The Aluminum&#x02019;s Ghost on the Lanthanum Salts</article-title><source>Curr. Med. Chem.</source><year>2005</year><volume>12</volume><fpage>1631</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.2174/0929867054367158</pub-id><pub-id pub-id-type="pmid">16022663</pub-id></element-citation></ref><ref id="B131-ijms-24-07228"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Winkelman</surname><given-names>M.D.</given-names></name>
<name><surname>Ricanati</surname><given-names>E.S.</given-names></name>
</person-group><article-title>Dialysis Encephalopathy: Neuropathologic Aspects</article-title><source>Hum. Pathol.</source><year>1986</year><volume>17</volume><fpage>823</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(86)80203-9</pub-id><pub-id pub-id-type="pmid">3733071</pub-id></element-citation></ref><ref id="B132-ijms-24-07228"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wills</surname><given-names>M.R.</given-names></name>
<name><surname>Savory</surname><given-names>J.</given-names></name>
</person-group><article-title>Aluminum and Chronic Renal Failure: Sources, Absorption, Transport, and Toxicity</article-title><source>Crit. Rev. Clin. Lab. Sci.</source><year>1989</year><volume>27</volume><fpage>59</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.3109/10408368909106590</pub-id><pub-id pub-id-type="pmid">2647415</pub-id></element-citation></ref><ref id="B133-ijms-24-07228"><label>133.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Walton</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Bioavailable Aluminum: Its Effects on Human Health</article-title><source>Encyclopedia of Environmental Health</source><publisher-name>Elsevier B.V.</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2011</year><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-52272-6.00715-7</pub-id></element-citation></ref><ref id="B134-ijms-24-07228"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M.Y.</given-names></name>
<name><surname>Ou</surname><given-names>S.H.</given-names></name>
<name><surname>Chen</surname><given-names>N.C.</given-names></name>
<name><surname>Yin</surname><given-names>C.H.</given-names></name>
<name><surname>Chen</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Aluminum Overload in the Reverse Osmosis Dialysis Era: Does It Exist?</article-title><source>Ren. Fail.</source><year>2022</year><volume>44</volume><fpage>1595</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1080/0886022X.2022.2104165</pub-id><pub-id pub-id-type="pmid">36190833</pub-id></element-citation></ref><ref id="B135-ijms-24-07228"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sherrard</surname><given-names>D.J.</given-names></name>
<name><surname>Walker</surname><given-names>J.V.</given-names></name>
<name><surname>Boykin</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Precipitation of Dialysis Dementia by Deferoxamine Treatment of Aluminum-Related Bone Disease</article-title><source>Am. J. Kidney Dis.</source><year>1988</year><volume>12</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/S0272-6386(88)80007-6</pub-id><pub-id pub-id-type="pmid">3400633</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-07228-f001"><label>Figure 1</label><caption><p>Main routes for Al into the brain. Red capillaries symbolize arterioles, while blue capilarries symbolize small veins.</p></caption><graphic xlink:href="ijms-24-07228-g001" position="float"/></fig><table-wrap position="float" id="ijms-24-07228-t001"><object-id pub-id-type="pii">ijms-24-07228-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of recommendations regarding aluminium exposure limits.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source of <break/>Exposure to Al</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Exposure to Al Limits</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comments</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organization, References</th></tr></thead><tbody><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Occupational exposure limits</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al alkyls, NOS&#x02014;PEL of 2 mg/m<sup>3</sup>;<break/>Al soluble salts&#x02014;PEL of 2 mg/m<sup>3</sup>;<break/>Al metal and oxide (total dust)&#x02014;PEL of 10 mg/m<sup>3</sup>;<break/>Al metal and oxide (respiratory fraction)&#x02014;PEL of 5 mg/m<sup>3</sup>;<break/>Al pyro powders&#x02014;PEL of 5 mg/m<sup>3</sup>;<break/>Al welding fumes&#x02014;PEL of 5 mg/m<sup>3</sup>;<break/>Al stearate&#x02014;PEL of 10 mg/m<sup>3</sup>;<break/>Al distearate&#x02014;PEL of 10 mg/m<sup>3</sup>;<break/>Al tristearate&#x02014;PEL of 10 mg/m<sup>3</sup>.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8-h TWA was used in this document.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cal/OSHA [<xref rid="B14-ijms-24-07228" ref-type="bibr">14</xref>,<xref rid="B15-ijms-24-07228" ref-type="bibr">15</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al (total dust)&#x02014;PEL of 15 mg/m<sup>3</sup>
<break/>Al (respirable fraction)&#x02014;PEL of 5 mg/m<sup>3</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OSHA [<xref rid="B14-ijms-24-07228" ref-type="bibr">14</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al (total dust)&#x02014;REL of 10 mg/m<sup>3</sup>;<break/>Al (respiratory fraction)&#x02014;REL of 5 mg/m<sup>3</sup>;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up-to-10-h TWA was used in this document.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIOSH [<xref rid="B14-ijms-24-07228" ref-type="bibr">14</xref>,<xref rid="B16-ijms-24-07228" ref-type="bibr">16</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Oral exposure</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TWI of 1 mg/kg bw/week</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFSA [<xref rid="B17-ijms-24-07228" ref-type="bibr">17</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NOAEL of 30 mg/kg bw/day;<break/>LOAEL of 50&#x02013;75 mg/kg bw/day;<break/>PTWI of 2 mg/kg bw.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Major contributors to the total oral Al exposure were cereals and cereal-based products, accounting for 20&#x02013;90% of total dietary Al exposure.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WHO [<xref rid="B18-ijms-24-07228" ref-type="bibr">18</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Drinking water</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">For small water treatment facilities&#x02014;0.2 mg/L<break/>For large water treatment facilities&#x02014;0.1 mg/L</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WHO [<xref rid="B19-ijms-24-07228" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05 to 0.2 mg/L</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al level belongs to secondary standards, regarding substances that could cause &#x0201c;cosmetic effects (such as skin or tooth discoloration) or aesthetic effects (such as taste, odor, or color)&#x0201d;.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPA [<xref rid="B20-ijms-24-07228" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freshwater (regarding aquatic life)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CMC of 1&#x02013;4800 &#x003bc;g/L<break/>CCC of 0.63&#x02013;3200 &#x003bc;g/L</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wide range of Al CMC and CCC is caused by significant dependence of Al&#x02013;bioavailability and certain factors (mostly important ones are total hardness, pH, and dissolved organic carbon).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPA [<xref rid="B21-ijms-24-07228" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Toys</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Dry, brittle, powder-like or pliable toy material&#x0201d;&#x02014;2250 mg/kg;<break/>&#x0201c;Liquid or sticky toy material&#x0201d;&#x02014;560 mg/kg;<break/>&#x0201c;Scraped-off toy material&#x0201d;&#x02014;28130 mg/kg.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCHEER suggests that additional exposure from toys should be minimized due to high exposure to Al from other sources.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCHEER [<xref rid="B22-ijms-24-07228" ref-type="bibr">22</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Al&#x02014;aluminium; bw&#x02014;body weight; Cal/OSHA&#x02014;California&#x02019;s Division of Occupational Safety and Health; CCC&#x02014;criteria chronic concentration; CMC&#x02014;criteria maximum concentration; EFSA&#x02014;European Food Safety Authority; EPA&#x02014;Environmental Protection Agency; LOAEL&#x02014;lowest-observed-adverse-effect level; NIOSH&#x02014;The National Institute for Occupational Safety and Health; NOAEL&#x02014;no-observed-adverse-effect level; NOS&#x02014;not otherwise specified; OSHA&#x02014;Occupational Safety and Health Administration; PEL&#x02014;permissible exposure limit; PTWI&#x02014;provisional tolerable weekly intake; REL&#x02014;recommended exposure limit; SCHEER&#x02014;Scientific Committee on Health, Environmental and Emerging Risks; TWA&#x02014;time-weighted average; TWI&#x02014;tolerable weekly intake; WHO&#x02014;World Health Organization.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-07228-t002"><object-id pub-id-type="pii">ijms-24-07228-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of food and beverage content of aluminium.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mean Al Content</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cheddar cheese, sharp</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.9 &#x000b1; 3.9 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B23-ijms-24-07228" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beer <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4&#x02013;4.2 mg/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bread</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;14 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cocoa powder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;312 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Doughnut</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 &#x000b1; 6 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B23-ijms-24-07228" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flour</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;19 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fruit juice <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4&#x02013;47 mg/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herb-teas</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14&#x02013;67 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pancake mix</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">620 &#x000b1; 460 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B23-ijms-24-07228" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pasta</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;76 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wine <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4&#x02013;15 mg/L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B24-ijms-24-07228" ref-type="bibr">24</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Al&#x02014;aluminium; <sup>a</sup> and mixed drinks containing beer, draught beer; <sup>b</sup> and fruit juice drinks; <sup>c</sup> and fruit wine.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-07228-t003"><object-id pub-id-type="pii">ijms-24-07228-t003_Table 3</object-id><label>Table 3</label><caption><p>Factors affecting gastrointestinal absorption of Al.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Higher Absorption</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lower Absorption</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acidic or alkaline</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B9-ijms-24-07228" ref-type="bibr">9</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al compound</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al chloride, nitrate, citrate, lactate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Al hydroxide</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B7-ijms-24-07228" ref-type="bibr">7</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Presence of other substances</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citrate, fluoride, maltol, lactate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silicate, phosphate, polyphenol, sialic acid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B4-ijms-24-07228" ref-type="bibr">4</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Other factors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Larger amount of ingested Al</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B12-ijms-24-07228" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iron deficiency in the diet</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B7-ijms-24-07228" ref-type="bibr">7</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="ijms-24-07228-t005"><object-id pub-id-type="pii">ijms-24-07228-t005_Table 5</object-id><label>Table 5</label><caption><p>Potentially neuroprotective agents for Al-induced diseases found in animal studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neuro-Protective Agent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neuroprotective Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Additional Information</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mouse</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Beer (Si)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of Al-induced prooxidant and proinflammatory actions by decreasing TBARS levels and the expressions of GPx and TNF&#x003b1; and increasing the expressions of SOD (MnSOD and CuZnSOD) and CAT.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other beer components possibly involved: alcohol, hop, polyphenols, and folic acid. Further studies considering the similar effects of non-alcoholic beer are needed.<break/>Harmful effects of alcohol consumption must be taken into account.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B107-ijms-24-07228" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD, PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuation of neuronal death against Al-induced neurodegeneration by:<list list-type="simple"><list-item><label>-</label><p>reduction of Al-induced oxidative stress,</p></list-item><list-item><label>-</label><p>prevention of Al-induced cyt c translocation,</p></list-item><list-item><label>-</label><p>up-regulation of Bcl-2,</p></list-item><list-item><label>-</label><p>down-regulation of Bax, p53, and caspase-3 activation,</p></list-item><list-item><label>-</label><p>reduction of DNA fragmentation,</p></list-item><list-item><label>-</label><p>attenuation of Al-induced mitochondrial swelling, loss of cristae, and chromatin condensation.</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;Quercetin may be used as a prophylactic in order to slow down the progression of neurodegenerative diseases such as Alzheimer&#x02019;s and Parkinson&#x02019;s disease&#x0201d;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B108-ijms-24-07228" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevention of Al-induced DAergic neurotoxicity and related locomotor deficiencies (displayed by restored immunoreactivity of TH in SNc and VTA).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Curcumin could be considered as &#x0201c;a natural drug conferring the protection of the brain from heavy metals induced neurotoxicity&#x0201d;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B109-ijms-24-07228" ref-type="bibr">109</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rat</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAE</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alleviation of cognitive impairment, cellular damage, neurodegeneration, and cholinergic activity<break/>through attenuation of:<break/><list list-type="simple"><list-item><label>-</label><p>Al-induced oxidative stress (normalization of the MDA content and CAT and SOD activity in the cerebrum and cerebellum)</p></list-item><list-item><label>-</label><p>AChE activity in the cerebrum and cerebellum</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAE not only prevents but also reverses the aforementioned Al-induced negative effects.<break/>&#x0201c;CAE could be used as an antioxidant, anti-cholinesterase, memory enhancer, and neuroprotective agent&#x0201d;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> [<xref rid="B110-ijms-24-07228" ref-type="bibr">110</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD&#x02014;Alzheimer&#x02019;s disease; Al&#x02014;aluminium; AUD&#x02014;Alcohol use disorder; Si&#x02014;silicon; TBARS&#x02014;thiobarbituric acid reactive substances; GPx&#x02014;glutathione peroxidase; TNF&#x003b1;&#x02014;tumor necrosis factor-alpha; SOD&#x02014;superoxide dismutase; MnSOD&#x02014;manganese SOD; CuZnSOD&#x02014;copper-zinc SOD; CAT&#x02014;catalase; Bcl-2&#x02014;B-cell lymphoma 2; Bax&#x02014;Bcl-2-associated X protein; PD&#x02014;Parkinson&#x02019;s disease; p53&#x02014;tumor protein 53; cyt c&#x02014;cytochrome c; DAergic&#x02014;dopaminergic; TH&#x02014;tyrosine hydroxylase; SNc&#x02014;substantia nigra pars compact; VTA&#x02014;ventral tegmental area; CAE&#x02014;ethanolic extract of <italic toggle="yes">Centella asiatica</italic>; MDA&#x02014;malondialdehyde; AChE&#x02014;acetylcholinesterase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>